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RESUMO 
A cardiomiopatia diabética (CMD) é vista como uma cardiomiopatia específica e 
definida por alterações estruturais e funcionais no miocárdio devido a anomalias 
metabólicas e celulares induzidas pela diabetes mellitus (DM). A transição das anomalias 
metabólicas precoces que precedem a DM, como a glicemia de jejum alterada e a 
intolerância à glicose, para um estado de diabetes pode levar muitos anos; no entanto, as 
estimativas actuais indicam que a maioria dos indivíduos neste estado de pré-diabetes 
eventualmente desenvolve DM. Durante o estado pré-diabético, o risco de eventos 
cardiovasculares está já aumentado e as anomalias cardíacas podem aparecer antes do 
diagnóstico da DM. A identificação precoce de alterações cardíacas em pacientes pré-
diabéticos/resistentes à insulina poderá ser a melhor estratégia para prevenir a evolução 
para fases mais graves da doença. 
Para elucidar se estados iniciais de disfunção cardíaca estão já presentes na pré-
diabetes com resistência à insulina, e os mecanismos envolvidos, testamos um possível 
modelo animal que pode mimetizar um estado pré-diabético em humanos com resistência à 
insulina, sem outros factores associados que podem levar à lesão/disfunção cardíaca, 
consistindo numa dieta rica em açúcares (35% de sacarose) durante 9 semanas. 
Dois objectivos específicos principais foram estabelecidos: a) caracterizar este 
modelo animal (em rato), no que concerne ao perfil glicídico, lipídico e insulínico; b) 
avaliar possíveis alterações cardíacas e os mecanismos subjacentes, determinando a 
pressão arterial e a frequência cardíaca, indicadores de trofismo cardíaco e do ventrículo 
esquerdo e a expressão proteica e/ou génica de marcadores de fibrose, hipertrofia, 
proliferação, apoptose, angiogénese, função endotelial, inflamação e stresse oxidativo.  
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Este modelo caracteriza-se por uma normoglicemia em jejum, acompanhada por 
hiperinsulinemia, resistência à insulina e tolerância à glicose alterada, em conjunto com 
hipertrigliceridemia, o que pode ser definido como um modelo animal de pré-diabetes. Este 
modelo animal poderá ser uma ferramenta útil para avaliar o impacto das perturbações 
metabólicas precoces no tecido cardíaco, independentemente de outros factores como a 
obesidade e a hipertensão, que não se verificaram. 
Relativamente ao impacto da dieta rica em sacarose no tecido cardíaco, os nossos 
resultados indicaram que 9 semanas de tratamento pode estar associado a alterações 
iniciais a nível cardíaco, como sugerido pelo aumento da razão entre o peso do ventrículo 
esquerdo e massa corporal e pelo aumento da expressão génica de BNP, juntamente com 
uma tendência para um aumento da expressão de outros mediadores de fibrose / hipertrofia 
(como TGF-β1, pró-colagénio III, TSP-1 e CTGF) e de angiogénese e lesão endotelial 
(VEGF e iNOS, respectivamente). Além disso, o stresse oxidativo parece ser um potencial 
mecanismo que contribui para as iniciais alterações cardíacas. Esta hipótese, que deverá 
merecer uma atenção posterior mais aprofundada, é sugerida pela tendência para valores 
aumentados de MDA no soro e no tecido cardíaco. Contudo, em nosso entender, poderá 
ocorrer um mecanismo de compensação em resposta à formação de espécies reactivas, 
evidenciado pelo aumento do estado antioxidante total sérico e pela expressão aumentada 
da SOD no tecido cardíaco, bem como pela expressão génica reduzida de HNE e RAGE. 
Estes resultados sugerem que 9 semanas de consumo de sacarose poderá ser um 
período curto para promover alterações mais profundas na disfunção cardíaca, mas as 
alterações iniciais poderão estar já em curso. Contudo, estudos adicionais (incluindo outros 
tempos de exposição e marcadores de miopatia) são necessários para uma melhor 
compreensão dos mecanismos moleculares e celulares subjacentes ao efeito da dieta rica 
em sacarose numa fase inicial da CMD. 
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ABSTRACT 
Diabetic cardiomyopathy (DCM) is viewed as a specific cardiomyopathy and defined 
as structural and functional changes in the myocardium due to metabolic and cellular 
abnormalities induced by diabetes mellitus (DM). The transition from the early metabolic 
abnormalities that precedes diabetes, for example impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT), to diabetes may take many years; however, current 
estimates indicate that most individuals with these pre-diabetic states eventually develop 
DM. During the prediabetic state, the risk of cardiovascular events is already increased and 
myocardial abnormalities might appear prior to the diagnosis of Type 2 DM. Thus, the 
earlier identification of cardiac changes in prediabetic/insulin resistance patients could be a 
better strategy to prevent the evolution to most serious stages of the disease. 
To elucidate whether the initial stages of cardiac dysfunction are already present in a 
prediabetic state with insulin resistance, and the mechanisms involved, we tested a putative 
animal model that might mimic a human prediabetic state of insulin resistance, without 
other complicating factors that could lead to cardiac events, consisting on a high sugar diet 
(35% of sucrose) during 9 weeks.  
Two main specific goals were pursued: a) characterize the animal (rat) model, 
concerning glycemic, lipidic and insulinic profile; b) evaluate possible cardiac alterations 
and the underlying mechanisms, assessing by blood pressure and heart rate, heart and left 
ventricle trophism indexes and protein and/or mRNA expression of markers of fibrosis, 
hypertrophy, proliferation, apoptosis, angiogenesis, endothelial function, inflammation and 
oxidative stress. 
This model is characterized by the presence of fasting normoglycemia, accompanied 
by hyperinsulinemia, insulin resistance and IGT, together with hypertriglyceridemia, which 
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might be defined as a prediabetic animal model. Since obesity and hypertension were not 
present, this animal model seems to be a useful tool to evaluate the impact of earlier 
metabolic perturbations on cardiac tissue and the existence of cardiomyopathy, 
independently of these confounding factors. 
Concerning the impact of the sucrose diet on cardiac tissue, our results indicated that 
9 weeks of treatment might be associated with initial changes at cardiac level, as suggested 
by the increased left ventricle mass/body weight ratio and increased of BNP mRNA 
expression, together with a trend to upregulation of other mediators of fibrosis/hypertrophy 
(TGF-β1, procollagen III, TSP-1 and CTGF) and of angiogenesis and endothelial lesion 
(such as VEGF and iNOS, respectively). In addition, oxidative stress seems to be a 
putative mechanism contributing to earlier cardiac changes. This hypothesis, which 
deserves further elucidation, is suggested by the trend to increased values of MDA in 
serum and heart tissue. However, according to our view, a compensatory mechanism 
against the generation of reactive species might occurs, evidenced by the increased serum 
total antioxidant status and cardiac overexpression of SOD, as well as by the 
downregulation of HNE and RAGE mRNA.  
The results suggested that 9 weeks of sucrose exposure might be a short period to 
promote pronounced changes related to cardiac dysfunction, but the initial changes might 
be already in course. However, additional studies (including other times of exposure and 
markers of myopathy) are needed to better understand the molecular and cellular 
mechanisms underlying the effects of HSu on this earlier phase of DCM. 
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1. Diabetes Mellitus – “the road to diabetic cardiomyopathy” 
1.1. General definition and epidemiology of Diabetes Mellitus 
Diabetes Mellitus (DM) describes a metabolic disorder of multiple aetiology, 
characterized by chronic hyperglycemia, with abnormal metabolism of carbohydrates, 
lipids and proteins, resulting from defects in the secretion and/or insulin action. The 
consequences of DM, although in the long-term, are various and includes chronic injury 
with dysfunction and failure of various organs and tissues. According to the World Health 
Organization (WHO) and the American Diabetes Association (ADA), DM can be 
classified into four different categories: type 1, type 2, other specific types of diabetes and 
gestational diabetes (WHO, 1999; ADA, 2004). Within these categories, the most frequent 
are type 1 DM (T1DM) and type 2 DM (T2DM), which are briefly described below. 
T1DM, also called insulin-dependent, or immune-mediated, is characterized by a 
deficiency of insulin production, due to an autoimmune destruction of insulin-secreting 
pancreatic islet beta (β)-cell, which are related to multiple genetic predispositions and 
environmental factors, or unknown etiologies, called idiopathic diabetes. T1DM patients 
are, therefore, dependent on exogenous insulin ("insulin dependent") requiring treatments 
based on multiple daily insulin injections to maintain adequate insulin and to control 
glucose levels. The onset of T1DM usually occurs in children and young ages and, 
therefore, can also be referred to as juvenile diabetes; however, it can also appear at any 
age. This type of diabetes represents about 5-10% of the population affected by the disease.  
T2DM is the most common endocrine deregulation worldwide, representing about 
90-95% of the diabetic population. In recent years, the global prevalence of T2DM has 
increased in such a way that has achieved epidemic proportions. Currently, there are over 
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336 million cases of diabetes and an increase to 552 million by 2030 is estimated by the 
International Diabetes Federation (IDF) (Figure 1). Statistically, DM affects 8.3% of global 
adult population and it is expected to rise to 9.9% in 2030 (IDF, 2011).  
 
The prevalence of DM, in percentage, is higher among men; however, there are more 
women with diabetes worldwide. The most important demographic change to the increased 
prevalence of DM is the worldwide aging population, translated into an increase in 
population over 65 years of age (Wild et al., 2004). Despite the prevalence of DM is 
increasing overall, the prevalence of T2DM has increased more than the prevalence of 
T1DM, due to sedentary lifestyle with lack of physical activity and increasing population 
of obesity, mainly in developed countries, but also in developing countries that are 
becoming increasingly industrialized (IDF, 2011). 
In Portugal, T2DM has also reached an epidemic status, with overwhelming 
consequences at various levels, including personal, social, family and economic. 
Figure 1. Regional and global projections for the number of people with diabetes (20-79 years) from 2011 to 
2030. Taken from IDF Diabetes Atlas, 5
th
 Edition (IDF, 2011). 
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According to data of the Annual Report of National Diabetes Observatory (“Observatório 
Nacional de Diabetes” - OND), the prevalence of diabetes in 2010 was 12.4% in the 
portuguese adult population, people aged 20 to 79 years, which corresponds to a total of 
about 901 thousands, with some difference between men (14.7%) and women (10.2%). 
The prevalence of undiagnosed diabetes is 5.4%, and 26% of portuguese population aged 
between 20 and 79 years has already a large predisposition to disease development (SPD, 
2012). 
Type 2 diabetes occurs predominantly in adults (people older than 40 years); 
however, there has been a rise in diagnosed cases of T2DM at increasingly younger ages, 
even adolescents, suggesting a linkage with the increase of childhood obesity (Schwartz 
and Chadla, 2008). This aspect is even more alarming when considered that over the past 
20 years its prevalence has increased dramatically among children and adolescents 
(Coopeland et al., 2005). 
1.2. Prediabetes and metabolic syndrome as predictors of diabetes 
T2DM is nowadays viewed as part of a continuum of metabolic abnormalities, which 
includes prediabetes and metabolic syndrome, involving specific defects in insulin 
signaling, as well as other metabolic perturbations. The term metabolic syndrome describes 
a group of metabolic alterations that predisposes to cardiovascular disease (CVD) and 
diabetes, associating risk factors, such as insulin resistance, hypertension, decreased 
circulating high-density lipoprotein cholesterol (HDL-c) and high triglycerides (TGs) 
levels. In the presence of these factors, there is a raised risk of about 1.5 to 3 fold greater to 
develop coronary heart disease (CAD) and a risk 3-5 fold higher for diabetes (Figure 2). As 
metabolic syndrome develops, there is a rise of prevalence of associated risk factors that 
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are observed many years before the diagnosis of T2DM. The high prevalence of the 
metabolic syndrome is a great motif of concern worldwide. 
Initially, T2DM is characterized by a state of insulin resistance, in which cells do not 
properly respond to insulin and, as a consequence, there is a compensatory increase of 
insulin secretion by pancreatic β-cells (hyperinsulinemia), in order to maintain 
normoglycemia, a process termed β-cell compensation. This phase is now viewed as a 
prediabetes state and is mainly characterized by two conditions: impaired fasting glucose 
(IFG) and/or impaired glucose tolerance (IGT). Over the years, the excessive function of β-
cells (“the β-cells overactivity”) may lead to their exhaustion and impaired secretory 
capacity, contributing to the β cells failure and, therefore, to a decreased insulin secretion 
which then results in hyperglycemia (Figure 2). Thus, T2DM ensues and its 
pathophysiology is characterized by peripheral insulin resistance, abnormal regulation of 
hepatic glucose production and decline in β-cell function, leading to eventual failure of 
these cells (Virally et al., 2007). 
 
 
 
 
 
 
Figure 2. Schematic representation of the metabolic syndrome development in the natural history of T2DM. 
As metabolic syndrome develops, there is a rise of prevalence of associated risk factors that are observed 
many years before the diagnosis of T2DM. Taken from Ramlo-Halsted and Edelman, (1999). 
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Prediabetes is an increasingly common condition, typically defined as blood glucose 
concentrations higher than normal, but lower than diabetes thresholds, being a high-risk 
state for diabetes development. Diagnostic criteria for prediabetes have changed over time 
and vary depending on the institution of origin. According to WHO, people are at high risk 
of developing diabetes if they have one of two distinct states: IFG, defined as a fasting 
plasma glucose (FPG) concentration of ≥6.1 and <7.0 mmol/L, without IGT; and IGT, 
defined as an FPG concentration of <7.0 mmol/L and a 2 h postload plasma glucose 
concentration of ≥7.8 and <11.1 mmol/L, measured during a 75 g oral glucose tolerance 
test (OGTT) (WHO, 2006). The ADA applies the same thresholds for IGT, but uses a 
lower cutoff value for IFG (FPG 5.6 – 6.9 mmol/L), and has introduced glycated 
haemoglobin A1c (HbA1c) 5.7 – 6.4% as a new category for high diabetes risk (ADA, 
2011). The term prediabetes has been criticised because many people with prediabetes do 
not progress to diabetes, and it might imply that no intervention is necessary because no 
disease is present. Furthermore, diabetes risk does not necessarily differ between people 
with prediabetes and those with a combination of other diabetes risk factors. Indeed, WHO 
use the term intermediate hyperglycemia and an International Expert Committee convened 
by the ADA prefers the “high-risk state of developing diabetes” than prediabetes (WHO, 
2006; International Expert Committee, 2009). 
The population-based US National Health and Nutrition Examination Survey 
(NHANES) suggests that 35% of US adults older than 20 years and 50% of those older 
than 65 years had prediabetes in 2005–08, defined by FPG or HbA1c concentrations. 
Application of these percentages to the entire US population in 2010 yielded an estimated 
79 million adults with prediabetes (Centers for Disease Control and Prevention, 2011). 
Prevalences of IFG and IGT vary between ethnic groups and both disorders are more 
common in people older than 40 years (Cowie et al., 2009). Additionally, IFG is more 
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prevalent in men than in women, although the reasons for this difference are poorly 
understood (Cowie et al., 2009). Figure 3 shows worldwide projections of IGT prevalence 
for 2030, according to the International Diabetes Federation (2011). The number of adults 
with IGT is expected to increase worldwide, reaching 472 million by 2030.  
 
 
 
 
 
Prediabetes was recognized is an independent predictor of conversion to type 2 
diabetes in “The Strong Heart Study”, which showed that most of them can be identified 
through a fasting glucose measure (Wang et al., 2010). Nguyen et al. (2010) reported in 
another study (The Bogalusa Heart Study) that fasting plasma glucose levels within the 
normoglycemic range in childhood is a predictor of prediabetes and T2DM in the 
adulthood. Several longitudinal studies support the hypothesis that prediabetes is a risk 
factor for diabetes and CVD (Meigs et al., 2002; DECODE study group, 1999; Unwin et 
al., 2002; Gabir et al., 2000; Stern et al., 2002). 
Prediabetes in Portugal reached, in 2010, 26% of the population aged between 20 and 
79 years, meaning that this percentage of individuals already has probably a large 
predisposition to disease development. Furthermore, about 38.4% of this population suffers 
Figure 3. Actual and projected prevalence of impaired glucose tolerance (IGT) by region in adults aged 20-
79 years in 2010 and 2030. Taken from Tabák et al. (2012). 
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from diabetes or prediabetes, corresponding to more than one third of the portuguese 
population (Figure 4). 
 
 
 
 
 
 
1.3. Diabetic complications 
The frequency, severity and progression of diabetic complications are related to 
levels of hyperglycemia, metabolic changes associated with the duration of disease and 
exposure to risk factors, and also with the genetic environment. Over the years, an 
alarming number of 40% of diagnosed patients with diabetes develop late complications of 
the disease in several organs, which are frequently not timely detected. Thus, it is essential 
that patients with diabetes make a control of the disease to prevent further complications. 
Patients with a diagnosis of diabetes can have many complications, either at the 
microvascular (retinopathy, nephropathy or peripheral neuropathy) and macrovascular 
(stroke, coronary heart disease, acute myocardial infarction or peripheral vascular disease) 
level (Figure 5), causing human suffering and significant costs in the context of economics 
of global health (Fowler, 2008). 
Figure 4. Prevalence of diabetes and prediabetes in Portugal in 2010. Adapted from SPD (2011). 
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Although microvascular complications are the major risk in T1DM, are also often 
present in patients with T2DM. These complications have been directly associated with 
glucose toxicity, with amplification of intracellular metabolic pathways, including the 
proteins glycosilation, the abnormal activation of signaling cascades, such as protein 
kinase C (PKC), the hexosamine and the polyol pathways, and elevated production of 
reactive oxygen species (ROS). The microvascular complications increase the risk of 
cardiovascular (CV) events in diabetic patients, which implies that these are related 
indirectly to the macrovascular diabetic complications. Several studies shows that different 
type of these complications, such as diabetic retinopathy (Son et al., 2011), diabetic 
polyneuropathy (Chung et al., 2011) and diabetic nephropathy (Gerstein, et al., 2001), are 
independently linked to a high risk of CV events. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic diagram of macro and microvascular complications of diabetes. Taken from Cefalu and 
Canon (2007). 
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Concerning the macrovascular complications, which are the leading cause of 
mortality in T2DM (representing 75-80% of deaths), there are no evidences of reduction of 
its evolution when the therapeutic intervention consists only on a better glycemic control 
(Castagno et al., 2011; Duckworth et al., 2009); thus, the control of other factors seem to 
be crucial. 
As obesity is strongly associated with T2DM, the excessive release of free fatty acids 
(FFAs) gives rise to a dyslipidemic phenotype typical of diabetes (hypertriglyceridemia 
and reduced HDL-c), which is related to a higher CV risk (Toth, 2004). Associated with 
dyslipidemia, there is frequently hypertension, present in 60% of the T2DM patients, thus 
increasing the rates of myocardial infarction and stroke. Although the strict control of 
hyperglycemia, per se, does not significantly reduce the incidence of myocardial infarction 
and mortality, most of the epidemiological and pathophysiological data suggest that 
hyperglycemia increases the rate of CV disease and aggravates the consequences. In any 
way, the attenuation of microvascular consequences justifies, by itself, an energetic effort 
to tightly control blood glucose (Beckam et al., 2002).  
To better recognize and evaluate the CVD, other factors should be considered, 
including the peaks of hyperglycemia, the oxidative stress and the endothelial dysfunction. 
The finding that the common element of the micro and macrovascular complications is the 
vascular endothelium and the fact that, in this, the entry of glucose into the cells do not 
require insulin leads to assign greater importance to the peak postprandial hyperglycemia, 
with consequent oxidative stress. The knowledge of these factors could lead to assess the 
insulin-resistance as a phenomenon of protection triggered by the body. Interestingly, the 
organs do not protected against the insulin resistance are precisely the most affected. 
Older age, high blood pressure and smoking history are also major risk factors for the 
development of macrovascular complications. Due to the accumulation of different risk 
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factors within one individual, the risk of developing macrovascular complications is 
substantially increased. 
In addition to the high prevalence rates, chronic complications of diabetes mean that 
the disease has a strong impact on the health budgets related with disease treatment and 
hospitalization, as well as with early disability, inability to work and decreased quality of 
life; thus, it is becoming a serious public health problem.  
1.3.1 Cardiac complications of T2DM 
T2DM is a major risk factor for the development of CVD. It is responsible for up to 
65% of all deaths in people with T2DM, as well as for substantial morbidity and loss of 
quality of life. T2DM can lead to CV damage in a number of ways. As T2DM progresses, 
the heart and blood vessels undergo changes and lead to a number of different CV 
complications (Tuomilehto and Lindstrom, 2003). Although CAD is two to three times 
more common in diabetic patients that in non diabetic individuals (Fisher, 2003), it is not 
the only CV complication. Several experimental, pathological, epidemiological, and clinical 
studies have shown an association between diabetes mellitus and cardiomyopathy. The 
term diabetic cardiomyopathy (DCM) has been introduced in 1972 by Rubler et al., based 
on postmortem observations of heart failure (HF) in diabetic patients free of detectable 
CAD, which was further confirmed in numerous other clinical studies (Galderishi et al., 
1991; Shrestha et al., 2009). This fact suggests that diabetes is able to lead to damage of 
cardiac tissue without depending on the co-existence of other CV risk factors.  
Diabetes is typically associated with multiple metabolic and physiologic 
abnormalities, such as hyperglycemia, peripheral insulin resistance, dyslipidemia, 
hypertension, and overweight or obesity, activation of multiple hormone and cytokine 
systems, each of which are most known risk factors for cardiac failure. However, it 
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remains unknown whose factors are more important to the overall incidence of cardiac 
failure in diabetic patients. 
2. The diabetic cardiomyopathy  
DCM, a distinct clinical entity, is currently viewed as a result of complex 
relationships between metabolic abnormalities that accompany diabetes and its cellular 
consequences, resulting in functional and structural changes in the myocardium that, in 
combination with other features, impair cardiac performance, ultimately resulting in 
cardiac failure (Fang et al., 2004; Tziakas et al., 2005) (Figure 6). 
Diabetic cardiomyopathy is defined as functional and structural changes at the level 
of myocardium, independent of hypertension, CAD, or any other known cardiac diseases, 
leading to HF (Zarich and Nesto, 1989; Hayat et al., 2004). Although diabetic patients are 
at increased risk of structural heart disease due to vascular complications, the concept of 
diabetic cardiomyopathy suggests a direct cellular insult to the myocardium. Therefore, 
patients with hypertension and CAD may well have myocardial changes related to these 
disease processes, but a specific cardiomyopathy may also affect the myocardium 
secondary to diabetes causing a synergistic adverse effect. 
2.1. Epidemiological data 
Diabetes has accounted for a significant percentage of patients with a diagnosis of 
HF in numerous epidemiologic studies (Tang, 2007). The Framingham study (Kannel et 
al., 1974), the United Kingdom Prospective Diabetic Study (Stratton et al., 2000), the 
Cardiovascular Health Study (Gottdiener et al., 2000) and the Euro Heart Failure Survey 
(Nieminen et al., 2006) all suggested that the presence of diabetes may independently 
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increase the risk of developing HF. Several clinical studies (Galderisi et al., 1991; 
Devereux et al., 2000; Bella et al., 2001; Liu et al., 2001) have suggested that there is a 
consistent association between DCM and the presence of cardiac hypertrophy and 
myocardial stiffness, both independent of hypertension. Such associations have provided a 
credible existence of DCM as a unique clinical entity. 
DCM has evolved from a nebulous concept to concrete reality over the years. 
Evolving evidence supports a strong association between diabetes and cardiomyopathy. In 
one of the largest epidemiologic studies, involving over 800.000 patients, diabetes was 
found to be independently associated with the occurrence of congestive HF after adjusting 
for left ventricular hypertrophy (LVH), hypertension, CAD, and atrial fibrillation 
(Movahed et al., 2005). Furthermore, higher prevalence of biventricular cardiomyopathy in 
diabetes patients (Movahed et al., 2007) is also suggestive of diabetes as an independent 
cause of cardiomyopathy. Whether there are other confounding factors that could lead 
independently to cardiomyopathy in diabetics is unclear. However, it is important to note 
that actually no specific histologic and/or biochemical markers for so-called ‘‘diabetes 
cardiomyopathy’’ has been found; so, other mechanisms of damage can coexist or be 
responsible of a cardiomyopathy developing in a diabetic patient. Hyperglycemia, insulin 
resistance, increased fatty acid metabolism, microcirculatory changes, sympathetic 
dysfunction, and fibrosis are considered to collectively contribute to its pathology. It is 
hoped that as the mechanisms of this cardiomyopathy in diabetics continue to be 
elucidated, they will provide the impetus for generating novel therapies tailored to reduce 
the risk of HF in patients with diabetes mellitus. 
DCM may be subclinical for a long time, before the appearance of clinical 
symptoms or signs. According to the molecular theory of DCM, hyperglycemia is the 
main pathogenetic factor, which causes abnormalities at the cardiac myocyte level, 
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eventually leading to structural and functional abnormalities. However, other factors seem 
to be involved in the evolution of the disease and several substrates have been suggested. 
During the last years, the structural functional, pathological and molecular aspects of the 
disease have been increasingly investigated, but the issue is far to be elucidated.  
The next section briefly review the main pathophysiological mechanisms underlying 
DCM on the light of the current knowledge. 
2.2. Cardiac changes 
Accumulating data from experimental, pathologic, epidemiologic, and clinical 
studies have shown that diabetes results in structural and functional cardiac changes. 
2.2.1. Structural changes 
A number of studies have shown structural changes in diabetic hearts in the absence 
of hypertension, CAD, and valvular heart diseases. One of the most important structural 
hallmarks of DCM is cardiac hypertrophy, and this, in turn, is a powerful predictor of CV 
events (Figure 6). 
Hypertrophy is a form of growth characterized by an increase in the average cell size 
of the constituting organ (in contrast to hyperplasia, in which the number of cells 
increases). Although LVH is more common, the right ventricle can also become enlarged 
or both may be affected. The common factor is that in physiological cardiac hypertrophy 
the intermittent load induces an increase in chamber wall thickness, which is compensated 
by an increase in ventricular volume, thus balancing wall thickness to chamber volume 
ratio (Dorn, 2007). Numerous studies have shown that patients with T2DM have LVH 
independent of other confounding factors, including hypertension (Devereux et al., 2000). 
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LVH in the diabetic patient generally represents a more advanced stage of the disease and 
may manifest after a longer period. The causes and mechanisms underlying LVH are 
poorly understood, and the predictive contribute of LVH to DCM is not entirely clear. 
Recently, however, clinical and animal studies have reported evidences implicating the 
diabetic milieu of hyperinsulinemia,
 
insulin resistance, hyperglycemia, and increased 
nonesterified fatty acids (NEFAs) in the pathophysiology of LVH in DM patients. For 
instance, insulin may act as a growth factor in the myocardium, which is supported by the 
experimental observation that sustained hyperinsulinemia leads to increased myocardial 
mass and decreased cardiac output in rats (Karaso et al., 2003; Holmäng et al., 1996). 
Higher circulating levels of the hormone leptin have also been linked to
 
the development of 
LVH in obese diabetic humans (Barouch et al., 2003). The consistency of results 
demonstrates a clear impact of DM, per se, on increased left ventricule (LV) mass that 
encompasses the development of diabetes-related LVH. 
Another mechanism proposed to explain cardiac alterations in DCM is related to the 
development of myocardial fibrosis (Figure 6). Cardiac fibrosis is the accumulation of 
interstitial glycoproteins and increased extracellular collagen matrix, leading to increased 
stiffening and reduced relaxation of the ventricles. Interstitial and perivascular fibrosis with 
significant increase in collagen deposition has frequently been observed in heart biopsy 
samples from diabetic patients without significant CAD (van Heerebeek et al., 2008). 
Similar findings have also been observed in animal models of DM (Mizushige et al., 2000; 
Tschöpe et al., 2004). 
The echocardiographic features of increased LV fibrosis appear in the form of 
impaired relaxation and diastolic dysfunction and it has been suggested that collagen is a 
major determinant of ventricular stiffness. Consequently, alterations in collagen phenotype 
may play an important role in the impaired LV diastolic filling that is typical of DCM (van 
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Heerebeek et al., 2008). In a study with prediabetic Otsuka-Long-Evans- Tokushima Fatty 
(OLEFT) rats, a correlation between increased extracellular collagen content and decrease 
in early mitral peak flow (decreased E/A ratio) was reported (Mizushige et al., 2000). The 
cause for the accumulation of cardiac fibrosis in diabetes is believed to result from 
decreased degradation of glycosylated collagen by matrix metalloproteinases and, 
conversely, from excessive production of collagen by fibroblasts due to increased renin-
angiotensin aldosterone system (RAAS) activation (Fang et al., 2004). 
In addition, an increased formation of advanced glycation end-products (AGEs) has 
also been reported to occur in the myocardium of DM patients, as a result of 
hyperglycemia (Basta et al., 2004). It has been demonstrated that collagen is particularly 
susceptible to AGEs cross-linking and this association not only leads to myocardial 
stiffness but also impairment of collagen degradation, leading to further collagen 
accumulation or fibrosis (van Heerebeek et al., 2008; Aronson, 2003). Furthermore, the 
impairment of LV diastolic function of patients with diabetes may be secondary to 
alterations in collagen structure, specifically increased collagen cross-linking or AGEs 
(Aronson, 2003), thus contributing to the myocardial fibrosis and decreased compliance 
characteristic of DCM. 
2.2.2. Functional changes 
In many cases, it has been found that abnormalities of diastolic function may 
advertise the subsequent progressive deterioration of cardiac function. The noninvasive 
assessment of diastolic dysfunction mainly relies on Doppler studies of diastolic transmitral 
inflow, flow velocities, flow patterns, isovolumic relaxation time, and deceleration time, 
which are the most common criteria used in its evaluation. Numerous authors have 
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suggested that the most frequent and earliest functional effect observed by 
echocardiography in type 2 diabetic hearts is impaired diastolic function (Shehadeh and 
Regan, 1995; Fang et a., 2003; Karamitsos et al., 2007). 
Diastolic dysfunction can be defined as a condition in which myocardial relaxation 
and filling are impaired and incomplete. It can manifest as reduced early diastolic filling, 
increased atrial filling, extended isovolumetric relaxation, and as an increased number of 
supraventricular premature beats (Schannwell et al., 2002). There is also an increased LV 
end-diastolic pressure and a decreased LV end-diastolic volume (Hamblin et al., 2007). 
It is important to note that the impairment of diastolic performance is non-specific 
and frequently observed in many diseases, such as hypertension, hypertrophic 
cardiomyopathy and CAD, while systolic function remains intact. However, several studies 
have shown that changes in diastolic function are common, in diabetic animals 
(Loganathan et al., 2006; Seneniuk et al., 2002) and patients (Vaninen et al., 1992; Boyer 
et al., 2004; Di Bonito et al., 1996), without any clinical manifestations of congestive HF. 
Indeed, evidence of diastolic dysfunction has been found in patients with impaired glucose 
tolerance (Celentano et al., 1995), with newly diagnosed diabetes or a short duration of the 
disease, and free of microvascular complications. Thus, the detection of diastolic 
dysfunction may be a useful marker for the prognosis of cardiac mortality in diabetic 
subjects. 
There are also numerous studies that have reported an association between diabetes 
and changes in systolic function. Systolic dysfunction is defined as the loss of the heart´s 
ability to pump arterial blood in the peripheral circulation and it is associated with a 
reduction of the LV ejection fraction, fractional shortening and cardiac output. These 
alterations of systolic function were proven in both human and animal models of T1DM 
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and T2DM (Mihm et al., 1991; Mytas et al., 2009). However, Radovits et al. (2009) 
suggest that systolic dysfunction may be more pronounced in type 1 DCM. 
In DCM, systolic dysfunction occurs late, often when patients have already 
developed significant diastolic dysfunction. The prognosis in patients with depressed 
systolic dysfunction is poor with an annual mortality of 15%–20%. The presence of 
systolic dysfunction in the early years of diabetes is still controversial, while diastolic 
dysfunction is more easily detected by Doppler echocardiography. The controversy of the 
early existence of systolic dysfunction in diabetes is probably related with the fact that 
current techniques used for systolic function evaluation are less sensitive than those used 
for diastolic dysfunction assessment. For this reason, more sensitive techniques for systolic 
assessment have been developed, such as strain, strain rate, and myocardial tissue Doppler 
velocity, which have allowed the detection of preclinical systolic abnormalities in diabetic 
patients (Murarka and Movahed, 2010). 
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2.3. Pathophysiology of diabetic cardiomyopathy 
T2DM causes metabolic deregulation and is associated with numerous risk factors 
which are coupled with cardiomyopathy and HF. Extensive cellular and molecular studies 
have been focused on the putative process of metabolic disturbances in the pathogenesis of 
cardiac dysfunction found in diabetes (Figure 6). The metabolic and structural disturbances 
putatively underlying the development of cardiomyopathy are following briefly discussed. 
 
 
 
Figure 6. Metabolic and structural abnormalities associated with type 2 diabetes mellitus that might underlie 
the development of diabetic cardiomyopathy. Taken from Nunes et al. (2012). 
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2.3.1. Myocardial hyperinsulinemia and insulin resistance 
Insulin is an anabolic hormone produced by pancreatic β-cells in the islets of 
Langherhans that plays a fundamental role in the regulation of glucose homeostasis. It is of 
great importance that blood glucose levels remain constant as persistently high blood sugar 
concentrations over many years can lead to the development of several clinical 
complications. 
Insulin acts on insulin sensitive tissues, such as brain, fat, muscle and liver, to allow 
the transport of glucose into cells. Insulin is released by the pancreas in response to various 
stimuli; however, the transport of insulin from the β-cells is mainly determined by the 
plasma glucose levels and the concentrations of amino acids and fatty acids (Waselle et al., 
2005).  
Although the main role of insulin is the regulation glucose levels, it is also an 
important mediator of metabolic and mitogenic cellular actions, including glycolysis, 
glycogenesis, lipid metabolism, DNA synthesis, gene transcription, mRNA turnover, 
protein synthesis and degradation, as well as cellular growth and differentiation. 
Impaired insulin action (or insulin resistance) is characterized by the impaired ability 
of insulin to stimulate glucose uptake in peripheral tissues, inhibition of lipolysis in the 
adipose tissue and hepatic glucose production, which are major metabolic dysfunctions 
associated with the early stages of T2DM. Elevated plasma insulin levels can lead to 
numerous metabolic and pathophysiological derangements in various tissues. In the heart, 
insulin resistance involves defects in insulin signaling and glucose transport in 
cardiomyocytes. Moreover, insulin resistance is also considered to be one of the main risk 
factors for CVD. 
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Insulin exerts its effects through initial binding to its cell-surface receptor. The 
insulin receptor (IR) consists of two extracellular α-subunits and two transmembrane β-
subunits which are linked to form α2β2 heterotetrametric complex (Ottensmeyer et al., 
2000). The binding of insulin to the α-domain of IR initiates a rapid conformational change 
in the receptor that leads to activation of the intracellular tyrosine kinase domain β-
subunits of the receptor. This allows the receptor to undergo a series of intramolecular 
transphophorylation reactions in which one β-subunit phosphorilated its adjoining partner 
on specific tyrosine residues. 
IR shares a similar structure with the insulin-like growth factor (IGF-1) receptor 
(IGF-1R), explaining cross-reactions and partially overlapping functions between the two 
receptors and their ligand. Once activated, IR phosphorylates a variety of important 
intracellular substrates on tyrosine, including IR substrate family members (IRS-1-4), 
isoforms of Src-homology-2-containing (Shc), Grb2-associated binder 1 (Gab1), Cas-Br-M 
(murine) ecotropic retroviral transforming sequence homologue (Cbl), the adaptor protein 
APS. However, IRS1 and Shc isoforms are those who play a key role in insulin signal 
transmission, serving as docking sites for connecting a variety of proteins and leading to 
adaptation of the signaling cascade (White, 2002). The tyrosine phosphorylation of these 
proteins creates recognition sites for additional effector molecules containing Src-
Homology-2 (SH2) domains, to form the ultimate productive insulin receptor complex. 
Accordingly, each scaffold protein can interact with different SH2-containing proteins that 
direct a pathway of signal transduction. 
In addition to tyrosine phosphorylation, both the insulin receptor and the IRS 
proteins undergo serine phosphorylation, which may attenuate signaling by decreasing 
insulin-stimulated tyrosine phosphorylation. These alterations in phosphorylations provide 
negative feedback to insulin signaling and serve as a mechanism for cross-talk from other 
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pathways that are involved in the development of insulin resistance (Pessin and Saltiel, 
2000).  
The insulin signaling involves two major signaling cascades: the phosphoinositide 3-
kinase (PI3K) and the extracellular signal-regulated kinase (ERK)/mitogen-activated 
protein kinase (MAPK) pathways. 
PI3K is a heterodimeric protein composed of a p110 catalytic and p85 regulatory 
subunit. This regulatory subunit contains SH2 domain that bind to phosphorylated tyrosine 
residues of IR or IRS adaptor proteins, which allosterically activates the preassociated 
p110 catalytic subunit to generate the lipid product phosphatidyl-inositol 3,4,5-
trisphosphate (PI3,4,5P3) from the substrate phosphatidyl-inositol 4,5-bisphosphate 
(PI4,5P2). The increase of PI3,4,5P3 at the plasma membrane induced the recruitment and 
co-localization of the phosphoinositide-dependent  protein kinase-1 (PDK1). Once 
recruited, PDK1 phosphorylates and activates other downstream serine-threonine kinases, 
including protein kinase B (PKB; also known as Akt) and atypical PKC isoforms (Alessi et 
al., 1997; Vanhaesebroeck and Alessi, 2000).  
The activation of the PI3K pathway and consequent increased activations of 
PKB/Akt permits the transport of glucose through the translocation and recruitment of 
glucose transporter GLUT-4 containing vesicles to the cell membrane in order to augment 
the uptake of glucose by facilitated diffusion. GLUT-4 is the major insulin-responsive 
glucose transporter, with a greater expression protein in the heart (Zorzano et al., 1997; 
Abel, 2004). Glucose transport and utilization by cardiac myocytes is critical for the 
maintenance of normal morphology and function. In agreement, GLUT4-knockout mice 
exhibit cardiac hypertrophy characterized by vascular sclerosis, interstitial fibrosis and 
concentric hypertrophy (Katz et al., 1995; Stenbit et al., 200). 
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The PI3K/Akt pathway culminates in many metabolic effects of insulin (Zecchin et 
al., 2004). Therefore, activation of PI3K/Akt has been associated with growth factor 
mediated cell survival and inhibition of apoptosis in response to various stimuli. Akt 
promotes cell survival by directly phosphorylating transcription factors that control the 
expression of pro-and antiapoptotic genes. Furthermore, in response to insulin, Akt 
promotes glycogen synthesis via serine phosphorylation and inactivation of glycogen-
synthase kinase-3 beta (GSK-3β), a well-recognized inhibitor of nuclear transcription 
governing the hypertrophic process, which is also involved in the regulation of apoptotic 
events. In addition, Akt activates the mammalian target of rapamycin (mTOR) that 
activates the p70 ribosomal subunit S6kinase-1, leading to increased protein synthesis 
(Khamzina et al., 2005; Manning, 2004; Shan et al., 2004). However, these actions 
mediated through the insulin receptor may be mitigated when insulin signaling through the 
PI3K/Akt-1 pathway is impaired during chronic hyperinsulinemia 
In the heart, the MAPK cascade represents an important mechanism for cellular 
stress response (Rose et al. 2010). This pathway involves tyrosine-phosphorylated Shc 
binding to SH2 domain of the adaptor protein growth factor receptor bound 2 (Grb-2), that 
results in activation of the next signal transduction protein Sos. Sos is a guanosine 
nucleotide exchange protein which continues the cascade of activation by converting a 
monomeric small G protein called Ras from its GDP-inactive mode to its GTP-active mode 
(Gibson and Harris, 2002), which then initiates a kinase phosphorylation cascade involving 
RAF, which function as an upstream kinase for MAPK kinase (MEK). MEK 
phosphorylates ERK 1/2 to activate MAPK on threonine and tyrosine residues, resulting in 
the activation and regulation of gene expression. 
The four most thoroughly investigated MAPKs include ERK1/2, ERK5, JNK and 
p38. p38 MAPK is activated by angiotensin II (Ang II), inflammation, oxidative stress and 
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ischemia (Gao et al. 2002; Zhang et al. 2004). Previous studies suggest that long-term, but 
not short-term, activation of the MAPK is deleterious as it increases fibrosis, hypertrophy 
and apoptosis (Kompa et al., 2008). Previous studies have shown that p38 induces collagen 
formation, connective tissue growth factor (CTGF) mRNA expression and increase in the 
pro-inflammatory cytokine interleukin-6 (IL-6) in the heart (Tenhunen et al., 2006). 
So, while the PI3K/Akt pathway plays an important role in the metabolic effects of 
insulin, mediates glucose uptake and, after activation, is associated with the development 
of physiological hypertrophy, the MAPK pathway is important on nonmetabolic mitogenic 
and growth effects of insulin, mediating the pathological hypertrophy. 
LVH may be associated with insulin resistance. Therefore, insulin resistance or 
chronic hyperinsulinemia is characterized by a specific impairment of PI3K-dependent 
pathway and by an insulin-induced activation of the MAPK pathway, which results in 
cardiac hypertrophy. It is known that activation of PI3K pathway results in increased 
endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production and that 
the activation of the MAPK pathway is involved in stimulation of the vasoconstrictor 
endothelin-1. In fact, this represents a mechanism associated with insulin resistance, thus 
contributing to endothelial dysfunction and increased blood pressure due to the impaired 
vasodilator action of insulin (Figura 6). 
Heart insulin resistance has been associated with changes of TRB3. TRB3 is a 
member of Mammalian tribbles homologs (TRB) protein family which is characterized by 
the presence of a domain homologous to serine/threonin kinase in the middle of molecule 
[kinase homology (KH) domain] (Hegedus et al., 2007). The KH domain of TRB lacks a 
functional ATP binding site and contains the variant amino acid residues that are essential 
for kinase catalytic activity. Thus, members of the TRB family are referred to as 
pseudokinase to reflect the view that they are not functional kinases (Boudeau et al., 2006). 
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Despite lacking kinase activity, KH domain of TRBs still contain substrate-binding domain 
through which TRBs interact with different factorsTRB3 is an inducible gene whose 
expression is modulated by metabolic stresses including endoplasmic reticulum stress, 
nutrient stress (e.g. amino acid and glucose deprivation) and insulin (Ohoka et al., 2005; 
Ding et al., 2008). By interacting with Akt, TRB3 negatively regulated insulin signaling, 
and consequently result in increased insulin resistance and diabetes-associated 
complications. Expression of TRB3mRNA is induced in the liver by fasting and is elevated 
in db/dbmice. Hepatic overexpression of TRB3 in amounts comparable to those in db/db 
mice promoted hyperglycemia and glucose intolerance (Du et al., 2003).These 
observations have led to the suggestion that TRB3 elevation contributes to insulin 
resistance.  
TRB3 also serves as a molecular switch and regulates the activation of the three 
classes of MAPKs. TRB3 binds to and regulates MAPK kinase, thus controlling the 
activation of MAPK by incoming signals (Kiss-Toth et al., 2004). However, the 
TRB3/MAPK signal-transduction pathway has not been investigated in vivo on cardiac 
tissues directly. Akt and MAPK are the most important pathways involved in selective 
insulin resistance (Jiang et al., 1999), and activated MAPK contributes to the development 
of cardiac fibrosis (Papakrivopoulou et al., 2004; Tang et al., 2008).  
Recently, the relationship among TRB3 expression, and development of diabetic 
cardiomyopathy was established (Ti et al., 2011). In this study, the authors found TBR3 
overexpression in rats with diabetes, which was paralleled by increased ER1/2 and JNK 
expression which is key mediator of the inflammatory pathway, whereas phosphorylarion 
of p38 MAPK was decrease, suggesting that the TRB3/MAPK signaling pathways 
participated in the pathogenesis of DCM. In addition, with TRB3 silencing, enhanced 
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phophoryation of ERK/MAPK was suppressed, whereas the impaired Akt activity was 
upregulated, resulting in improvement of selective insulin resistance.  
2.3.2. Glucotoxicity and oxidative stress 
Hyperglycemia, a consequence of decreased glucose clearance and augmented 
hepatic gluconeogenesis, has been indicated as one of the major causes of DCM, due to 
activation of several mechanisms, leading to an increase in oxidative stress, which is 
defined as an imbalance between the production of ROS and antioxidant defense 
mechanisms. 
ROS are chemical compounds that result from the activation or reduction of 
molecular oxygen or derivatives of the products of this reduction, such as the superoxide 
anion and hydroxyl radical (Irani, 2000). ROS may have harmful consequences for the 
heart cells, including DNA damage and apoptosis, which in turn may promote cardiac 
dysfunction leading to structural and functional abnormalities that are associated with 
DCM (Figure 6). 
Hyperglycemia induces oxidative stress by several pathways, such as increased 
activation of the polyol and hexosamine pathways, increased formation of AGEs and 
activation of classical isoforms of PKC, which induce increased production of 
mitochondrial ROS, nonenzymatic glycation of proteins and glucose auto-oxidation. 
Activation of these pathways corresponds to an increased glucotoxicity, which may cause 
cellular injury. They are also associated not only with the development of diabetic 
complications but also with insulin resistance and pancreatic β-cell dysfunction. 
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i) Polyol pathway 
The polyol pathway reduces toxic aldehydes generated by ROS to inactive alcohols. 
Aldose reductase (AR), via the consumption of nicotinamide adenine dinucleotide 
phosphate (NADPH), is responsible for the initial and rate-limiting step in the process. 
Glucose can be reduced to sorbitol, and eventually fructose, through this pathway, but AR 
has a low affinity for glucose at normal concentrations. Elevated intracellular glucose can 
increase AR activity, resulting in significantly decreased NADPH. NADPH is also 
required for glutathione reductase activity, which reduces glutathione (GSH)–a major 
mechanism for reducing intracellular oxidative stress. Decreased NADPH GSH reductase 
activity ultimately increases oxidative stress and activates pathways that increase cellular 
damage (Rambhade et al., 2005) 
ii) Hexosamine pathway and glucose auto-oxidation 
Hyperglycemia increases flux through the hexosamine pathway by providing more 
fructose-6-phosphate (G-6-P) for glutamine fructose-6-phosphate amidotransferase, the 
rate-limiting enzyme of the pathway. The increased flux through the hexosamine pathway 
increases tissue concentration of a hexosamine metabolite, UDP-N-acetylglucosamine. 
This may lead to O-linked glycolisation of proteins on serine and threonine residues, which 
then compete with serine and threonine phosphorylation of these sites (McClain, 2002), 
providing a mechanism by which hyperglycemia could interfere with insulin transduction 
pathways. Activation of the hexosamine pathway may also occur by other metabolites, 
such as FFAs, and the ability of a variety of nutrients to activate hexosamine pathway has 
led to the theory that this pathway serves as a general nutrient sensing pathway, through 
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which hyperglycemia or hyperlipidemia could decrease insulin sensitivity when nutrient 
excess prevails. 
The effect of hyperglycemia on flux of the hexoasamine pathway probably reflects 
increased G-6-P levels, which result from inhibition of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) by ROS. Recently, ROS formation due to glucose auto-oxidation 
has been hypothesized to play a role in the pathogenesis of DCM in diabetic patients; 
however, no unifying hypothesis exists to explain how glucose auto-oxidation causes any 
of the complications seen in diabetes. 
iii) Advanced glycation end-products (AGEs) 
As already noted, the increase of AGEs is highly associated with myocardial fibrosis 
in diabetic hearts by affecting the structural components of the extracellular matrix, such as 
collagen, indicating the potential role of AGEs in DCM (Candido et al., 2003). AGEs are a 
heterogeneous group of proteins, lipids and nucleic acids that are formed by nonenzymatic 
glycosylation. They bind to specific cell surface receptors [receptor for AGEs (RAGE)] 
and, in the cascade of intracellular signal transduction, form oxygen free radicals and 
promote the activation of gene expression. This receptor ligation increases the production 
of the transcription factor nuclear factor-κB (NF-κB), also causing increased oxidative 
stress, and it is critically involved in the mechanisms of endothelial dysfunction and 
platelet activation. The AGE-RAGE axis besides playing a role on oxidative stress 
represents a key mediator of inflammation (Cziszar and Ungvari, 2008). 
The RAGE is a multi-ligand member of the immunoglobulin superfamily of cell 
surface molecules that binds to a wide variety of ligands that are susceptible to aggregation 
and posttranslational modifications. This receptor is widely expressed in the peripheral and 
central nervous systems. A series of ligands of RAGE, as well as the activation of RAGE 
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itself, can induce oxidative stress (Irani, 2000)
 
and exert direct effects on cardiac 
remodeling due to adhesive and growth-regulating properties. 
RAGE has an endogenous secretory receptor form, called soluble RAGE (sRAGE), 
which could exert antiatherogenic effects by acting as a decoy. Reduced sRAGE levels in 
CAD subjects with normal levels of low-density lipoprotein (LDL) cholesterol could also 
raise the possibility that the measurement of sRAGE level may improve risk assessment 
among normolipidemic subjects (Falcone
 
et al., 2005). sRAGE levels were significantly 
higher in type 2 diabetic patients than in non-diabetic subjects and positively associated 
with the presence of CAD (Nakamura et al., 2007). Plasma sRAGE levels are positively 
associated with endothelial function and predict CV events in nondiabetic patients with 
suspected coronary artery disease, suggesting a pivotal role in atherothrombosis (Chiang et 
al., 2009). Low levels of sRAGE have also been associated with stroke, especially in 
subjects without identifiable conventional risk factors, being even proposed as a potential 
biomarker
 
(Park et al., 2009). 
In diabetes patients, elevated serum and tissue contents of AGEs have been found, 
which then activate RAGE (Yamagishi et al., 2007; Yan et al., 2007). Further, in the heart 
tissues of diabetic rats, an increased expression of RAGE has been found, which seems to 
be associated with CTGF (Candido et al., 2003). Overexpression of RAGE in diabetic 
hearts of animals implies a role for this receptor in mediating AGE-induced myocardial 
structural alterations. In addition to AGE-induced fibrosis, several lines of evidence have 
suggested that AGE accumulation is associated with impaired calcium homeostasis and 
mitochondrial function and altered expression and function of both the ryanodine receptor 
and sarcoplasmic/endoplasmic reticulum Ca
2+
-ATPase (SERCA), contributing to reduction 
of calcium entry in the myocyte and, consequently, impaired change myocardial 
contractility (Bidasee et al., 2003). 
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iv)  Activation of protein kinase C isoforms 
PKC is a serine kinase that has a number of potential substrates, including the IR 
(Newton, 1995). PKC is activated by diacylglycerol (DAG), the concentration of which 
increases in a glucose-dependent manner during hyperinsulinemia (Chen et al., 1994). 
Subsequential PKC activation can lead to serine phosphorylation and inhibition of the 
insulin receptor and IRS proteins (Virkamaki, 1999). 
PKC pathway activation is also correlated with biochemical changes underlying the 
development of DCM. These changes include increased vascular permeability and lead to 
blood vessel constriction and changes in blood flow, stimulating neovascularization, 
proliferation and apoptosis of endothelial cells, and activation of several factors, such as 
transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF) and 
IGF-1 (Koya and King, 1998; Das Evcimen and King, 2007).
 
Moreover, a recent study 
indicated that PKC promotes cardiac hypertrophy by activating NF-κB (Min et al., 2009). 
2.3.3. Lipotoxicity 
Diabetic hearts are also characterized by increased myocardial fatty acids uptake and 
TGs levels. FFAs, once inside the cell, are converted into acetyl coenzyme A derivatives 
that will activate the isoforms of PKC, an intracellular enzyme with the ability to block the 
insulin signaling pathways which, in turn, will block the entire cascade of subsequent 
reactions preventing insulin action (Perseghin et al., 2003).
 
In the presence of elevated 
levels of FFAs, there is a competition of these with glucose as energy substrate, with a shift 
in energy production from β-oxidation of FFAs (Rodrigues et al., 1998), leading to 
decreased glucose utilization and oxidation, with increased glucose levels and release 
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stimulation, increasing the amount of insulin and promoting insulin resistance (Poitout and 
Robertson, 2002) 
The increase of FFAs and its metabolism leads to intracellular accumulation of toxic 
fatty acids intermediates, such as ceramide and diacylglycerol, as well as the formation of 
ROS, which contribute to oxidative stress, cardiomyocyte apoptosis, and increased 
myocardial oxygen consumption. This results in reduced myocardial high-energy reserves 
and impaired contractility, promoting mitochondrial uncoupling and leading to decreased 
adenosine triphosphate availability (Khullar et al., 2010; Eckel and Reinauer, 1990). 
Therefore, all these mechanisms may be involved with a reduced cardiac performance, thus 
contributing to the pathogenesis of DCM. 
Furthermore, the cardiac lipotoxicity in DCM also involves the activation of 
transcription factors that further affect FA uptake and oxidation. Therefore, FFAs 
intracellular deposition is responsible for the saturation of the mitochondrial capacity of 
oxidation, thus activating transcription factors, including the peroxisome proliferator-
activated receptors (PPARs). Although PPARs are key regulators of FA metabolism in the 
heart, recent studies have shown that cardiac overexpression of PPAR-alpha (PPARα) and 
PPAR-gamma (PPARγ) causes lipotoxic cardiomyopathy and steatotic cardiomyopathy 
(Finch et al., 2003; Son et al., 2007). 
In animal models of obesity and diabetes an increase in apoptosis has been shown to 
occur in the heart (Barouch et al. 2006). Several mechanisms have been proposed to lead to 
the increase in apopotic cell death, including gluco and lipotoxicity, mitochondrial 
dysfunction and increased RAAS activity. All of these lead to an increase in the build-up 
of ROS. The high circulating and intracellular stores of fatty acids leads to alternative non-
oxidative forms of energy production that result in the accumulation of toxic by-products. 
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The reactive lipids react with oxygen products to produce toxic reactive lipid species that 
may lead to increased cell death. 
2.3.4. Endothelial dysfunction  
Endothelial dysfunction is also involved in the pathogenesis of DCM. The 
endothelium regulates the vascular tone by releasing vasodilator and vasoconstrictor 
substances. Endothelial dysfunction expresses the malfunction of the vascular endothelium 
and usually reflects a reduced bioavailability of NO, which is an important vasodilator. 
Furthermore, NO also has anti-hypertrophic, anti-proliferative, and anti-inflammatory 
properties and inhibits leukocyte adhesion, limits adhesion and aggregation of platelets, 
and reduces the expression of plasminogen activator inhibitor 1 (PAI-1), a pro-thrombotic 
protein associated with vascular homeostasis. Diabetes is associated with decreased 
expression of eNOS and decreased production of NO through the inhibition of the IRS-
PI3K-Akt-eNOS-NO (Figure 7). However, due to increased oxidative stress, an excess of 
NO becomes cytotoxic. Part of its toxicity is due to its reaction with superoxide, resulting 
in peroxynitrite formation and decreased of NO bioavailability (Yu et al., 2011), causing 
endothelial dysfunction and leading to impaired vasodilatation. A relationship between the 
excessive cardiac production of ROS and endothelial dysfunction has been demonstrated in 
animal models of type 1 and T2DM and in humans with T2DM (Guzik et al., 2002). 
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2.3.5. Inflammation 
Chronic low-grade inflammation is commonly associated with obesity and T2DM, 
and clear evidence has emerged to suggest that inflammatory process also contributes to 
the pathogenesis of DCM. 
The activation of several signaling pathways, such as NF-κB, c-jun NH2-terminal 
kinase (JNK) or p38-MAPK, could mediate a state of inflammation, which is linked to 
insulin resistance, thus playing an important role in diabetic complications (Lorenzo et al., 
2011; Kaneto et al., 2004; Li et al., 2007).
 
In fact, NF-κB represents one of the most 
important mediators of the inflammatory process. Activation of NF-κB is associated with 
the increased release of cytokines, such as tumor necrosis factor-alpha (TNF-α), which is 
often involved in cardiac damage and leads to NF-κB activation, thus contributing to the 
Figure 7. Impairment of insulin – PI3K – Akt – eNOS – NO signaling defines a key characteristic of insulin 
resistance and myocardiac dysfunction.Taken from de Yu et al. (2011). 
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intensification of adverse effects in diabetic hearts (Lorenzo et al., 2011). Elevated 
inflammatory mediators cause insulin resistance since they reduce the IRS-1 tyrosine 
phosphorylation, and the activation of PI3K and AKT, decreasing insulin signaling (Jager 
et al., 2003). Moreover, elevated inflammatory markers may exacerbate insulin deficiency 
by impairing β cell function and inducing cell death, which implicate a progressive decline 
in β -cell mass (Donath et al., 2003). 
Elevated inflammatory cytokines, such as TNF-α, IL-6, cell adhesion molecules, 
including vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion 
molecule-1 (ICAM-1), acute phase reactants, such as C-reactive protein (CRP), PAI-1 and 
other biological markers of inflammation have been found in circulation and in the diabetic 
hearts o T2DM patients (Yu et al., 2011; Mano et al., 2011). Accumulating data have been 
demonstrated that elevated levels of several inflammatory markers, such as interleukin-1 
beta (IL-1β) and TNF-α, are implicated in diabetic cardiomyopathy, increases epicardial 
thickness, promotes myocyte contractile dysfunction, thus depressing myocardial function, 
contributing to HF (Westermann et al., 2006). Moreover, cardiac overexpression of TNF-α 
has been associated with cardiac hypertrophy
 
and fibrosis, as well with left ventricular 
dysfunction (Yokoyama et al., 1997; Sun et al., 2004). Furthermore, IL-6 has been also 
described as an inducer of myocardial damage. Therefore, excessive production of IL-6 
can promote LV dysfunction and cardiac hypertrophy under acute myocardial infarction 
(Younce et al., 2010). 
Although the inflammatory response seems to be linked with DCM development, its 
presence and influence differs in the early and the long-standing stages of the disease. 
Therefore, according to Ares-Carrasco et al. (2009),
 
using normotensive and spontaneously 
hypertensive rats (SHR)
 
with T1DM induced by streptozotocin, myocardial fibrosis and 
apoptosis are features of myocardial damage secondary to long-term experimental 
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diabetes, but inflammation was modulated by the expression of anti-inflammatory 
molecules, in particular IL-10, and antioxidants. The authors also found interesting effects 
when diabetes coexisted with hypertension. DCM and hypertensive cardiomyopathy share 
some typical features, including functional and structural changes, which contribute to 
cardiac tissue impairment. 
Additionally, according to the proteomics studies of Ares-Carrasco et al. (2012) in 
SHR and SHR/DM1 rats, when diabetes and hypertension coexist, hearts present with 
impaired expression of metabolic, hypertrophic, and apoptotic proteins, against what 
occurs in the early stages of injury, in which fibrotic and inflammatory rates are not 
additive. Furthermore, they suggest that in such a stage of diabetes and hypertension, 
PPAR-α activation, as a compensatory response to the metabolic, apoptotic, and 
hypertrophic impairment, could reduce cardiac hypertrophy. In this sense, therapeutics 
with PPARα agonists could have beneficial anti-hypertrophic effects on the hypertensive 
DCM.  
As mentioned, hyperglycemia induced-oxidative stress is strongly correlated with 
development of diabetic cardiomyopathy. In fact, hyperglycemia has been shown to 
activate various oxidative stress-responsive/proinflammatory transcription factor, including 
NF-κB, to induce collagen and fibronectin synthesis, as well as to stimulate the production 
of inflammatory cytokines. 
A recent study suggests that hyperglycemia-induced cardiomyocyte apoptosis is 
mediated by production of monocyte chemotactic protein-1, providing a molecular link 
between hyperglycemia, inflammation and DCM (Kaneko et al., 1997). Yu et al. (2011)
 
indicated that hyperglycemia-induced diastolic dysfunction may be mediated partly by the 
macrophage migration inhibitory factor, suggesting that the NF–κB pathways may be 
involved in this process. In addition, in the same study, the authors demonstrated the 
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macrophage migration inhibitory factor effects in abnormal upregulation of G protein–
coupled receptor kinase 2, which may be associated with a constant activation of beta1-
adrenergic receptor and HF development. The activation of the RAAS seems to be another 
factor that plays an important role in modulation of inflammation in DCM. Ang II not only 
induces vasoconstriction, cell growth and oxidative stress but also stimulates inflammation. 
Ang II is able to induce cytokine release (Schieffer et al., 2000), also stimulating the 
production of PAI-1 and pro-inflammatory transcription factors, such as NF-κB (Hernández-
Presa et al., 1997), which in turn regulate adhesion molecule (VCAM-1 and ICAM-1) and 
the expression of several cytokine, as already mentioned. 
2.3.6. The rennin-angiotensin-aldosterone system (RAAS) 
The rennin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that plays 
a major role in the homeostatic control of arterial pressure by regulating blood vessel 
constriction. Deregulation of RAAS plays an important role in pathological origin of renal 
diseases, CVD and arterial hypertension (HTA) and also contributes to the development of 
cardiomyopathy. 
Activation of the RAAS, locally and systemically, is strongly associated with the 
development of insulin resistance and the onset of type 2 diabetes (Niklason et al., 2004; 
de Kloet et al., 2010; Abuissa et al., 2005). In diabetes, excessive activation of the RAAS 
has been described (Hayashi et al., 2010; McGuire et al., 2008). Since RAAS 
overactivation has been associated with some of the hallmarks of DCM, such as increased 
fibrosis, angiogenesis, oxidative damage and cardiomyocyte and endothelial cell apoptosis 
and necrosis, it has increasingly recognized as an important factor in the progression of the 
disease (Fang et al., 2004; Privratsky e al., 2003). 
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Ang II is the main physiological effector molecule of RAAS; its release in the 
myocardium, due to the upregulation of RAAS, has diverse and widespread actions that 
affect cardiac function (Fyhrquist and Saijonmaa, 2008). Animal experiments have also 
shown that Ang II infusion induces insulin resistance (Richey et al., 1999) and increased 
levels of Ang II and Type 1 receptors (AT1-R) have been show in diabetic rats (Singh et 
al., 2008; Lee et al., 2008; Siddiqui et al., 2007). Ang II can interfere with all intracellular 
signaling of insulin receptors, preventing the glucose receptor translocation, thus being one 
of the pathophysiologic bases of insulin resistance. AT1-R mediate most physiological and 
pathophysiological and deleterious effects attributed to Ang II. In the adult CV system, 
Ang II induces its vasoconstrictive effects on cardiomyocytes through ligand binding to the 
AT1-R (Fiordaliso et al., 2000). The rise of Ang II in diabetic rats has been related to 
cardiomyocyte hypertrophy and apoptosis, and it stimulates the proliferation of cardiac 
fibroblast and synthesis of collagen, causing myocardium interstitial and perivascular 
fibrosis, ventricular myocardium rigidity and impaired diastolic function, leading to the 
clinical symptoms of DCM (Brilla et al., 1997; Dostal et al., 2000). 
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2.4. Are there earlier cardiac changes in (pre)diabetes? 
A link between DM and HF has been well-recognized for more than a century. HF is 
also closely linked to abnormal glucose regulation (AGR) and insulin resistance in patients 
without DM and, similarly, these conditions commonly coexist. In epidemiological studies, 
each condition appears to predict the other. The prevalence of AGR/IR in HF patients 
without DM is significantly under recognized and, as yet, the optimal method for screening 
for these abnormalities in the outpatient setting is unclear (Mamas et al., 2010). 
Clinical studies indicate a high prevalence of insulin resistance and impaired fasting 
glucose among non-diabetic patients with cardiovascular disease (Berry et al., 2007; 
Bartnik et al., 2004). Furthermore, the prevalence of prediabetes is substantial among 
adults with CHD and likely underestimated because of suboptimal screening (Kilmer et al., 
2011). Several longitudinal studies support the hypothesis that prediabetes is a risk factor 
for diabetes and CVD (Coutinho et al., 1999; Meigs et al., 2002; DECODE study group, 
1999; Gabir et al., 2000; Stern et al., 2002). 
De Marco et a. (2011) evaluated whether prediabetes, as measured by IFG, is 
associated with cardiac alterations independently of major confounders in a population-
based sample of adolescents and young adults. They found that prediabetic individuals had 
a significantly higher prevalence of LVH than participants with normal fasting glucose, 
reflecting important target organ damage already present at an early phase of alteration of 
glucose metabolism. Furthermore, the presence of geometry-related left ventricular 
functional alterations was found in prediabetic subjects. This fact is important, since there 
is a strong relation between LVH and adverse cardiovascular outcomes (Levy et al., 1990), 
recommending targeting prevention strategies in this subpopulation.  
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Postprandial, but not fasting, hyperglycemia is known to be a better predictor of 
major cardiovascular events or total mortality, but the impact of postprandial or fasting 
glucose levels on LV diastolic function has not been elucidated (Coutinho et al., 1999; 
DECODE Study Group, 2001). Recently, Shimabukuro et al. (2011) showed, in humans, 
that impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular 
diastolic dysfunction, and Wu et al. (2007) previously described epidemiological evidence 
of altered cardiac autonomic function in subjects with IGT but not isolated IFG, as 
previously suggested (Fujita et al., 2007). However, according to Diakakis et al. (2005), 
IGT patients have an increased HR and elevated cytokine levels, suggesting that these 
changes could serve as an index of the primary atherosclerotic process. 
Two recent studies, the “ADVANCE” trial (Zoungas et al. 2009; Patel et al., 2008) 
and the “ACCORD” trial (Gerstein et al., 2008; ACCORD Study, 2010), reported no 
significant benefit from intensive HbA1c lowering in terms of cardiovascular outcomes in 
subjects with long-standing diabetes. Therefore, early interventions seem to be advisory. 
However, the state of myocardial performance in prediabetes has received little attention.  
An ongoing debate is whether prediabetes deserves targeted identification and 
clinical intervention, as well as the search for feasible biomarkers for diagnosis and 
treatment (Tabák et al. 2012; Grundy, 2012; Ratner and Sathasivam, 2011; Pour et al., 
2011; DeFronzo and Abdul-Ghani, 2011). The epidemiological relation between 
prediabetes and macrovascular disease can be confounded by clustering of vascular risk 
factors within individuals. Blood glucose in the prediabetic range is correlated with many 
risk factors, including general and central obesity, blood pressure, and triglyceride and 
lipoprotein concentrations (The Emerging Risk Factors Collaboration, 2010). Thus, well 
defined and characterized animal models could be important tools to study the mechanisms 
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underlying prediabetes evolution to diabetes and associated complications, including 
cardiomyopathy. 
3. The high-sucrose diet as an experimental model of (pre)diabetes 
cardiomyopathy 
Animal models have become a useful tool for investigating various genetic, 
environmental, behavioral and pharmacologic factors that play a role in metabolic 
abnormalities. Various animal models of diabetes have been used to study the causes and 
underlying cellular events of diabetic cardiomyopathy. However, one major impediment to 
progress in the knowledge of the appropriate animal models, and a one major difficulty is 
the presence of important factors, such as obesity and hypertension, which displays 
susceptibility to cardiomyopathy.  
Since in the prediabetic state cardiac alterations may already be present, an 
understanding of the cellular effects of these metabolic disturbances on cardiomyocytes in 
the prediabetic state should be useful in predicting the structural and functional cardiac 
consequences. Experimental support is limited with most work focusing on chemically 
induced type 1 models of the disease that ultimately represent an extreme of the metabolic 
profile (rarely encountered in clinical practice) or type 2 models burdened with other 
element(s) of the metabolic syndrome and thus the evidence is scarce regarding the 
mechanisms involved in cardiomyopathy in this stage of disease. Therefore, animal models 
of prediabetes could help with the understanding of the events leading to the appearance of 
clinical symptoms. To elucidate whether the alteration at cardiac level are already present 
in prediabetic state and what the underlying mechanisms we pretend to use an animal 
model that presents with relatively minor metabolic abnormalities, consistent with 
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prediabetic insulin resistance in humans (Pagliassotti et al.,1996; Podolin et al., 1998), and 
that mimics early stages of type 2 diabetes, without other complicating factors that could 
lead to cardiac events. 
Dietary factors are likely to be of importance in the etiology of the metabolic 
syndrome in humans. Several studies have demonstrated that the macronutrient 
composition of the diet is an important environmental determinant of the quality of insulin 
action (Storlien et al., 1988; Lombardo et al., 1996; Besesen, 2001). Most studies have 
examined the relationship between sucrose and insulin resistance. High sucrose (HSu) 
intakes have been shown to contribute to conditions such as hypertyglyceridemia, impaired 
glucose tolerance and hyperinsulinemia in rat models, mimicking the features of metabolic 
syndrome that precede the development of T2DM; however, the underlying mechanisms 
have not been elucidated. 
Some of the controversy regarding the ability of sucrose to produce insulin resistance 
is probably due to different experimental conditions, including different models, dose of 
sucrose and/or duration of exposure to the nutrient.  
Pagliassotti et al. (1995) demonstrated in the rat that the quantity of dietary sucrose 
influenced the time course of the development of insulin resistance in a tissue-specific 
manner, in that consumption of a diet high in sucrose (68% of kcal as sucrose) resulted in 
hepatic and peripheral insulin resistance within 8 weeks, whereas consumption of a diet 
lower in sucrose (18% of kcal as sucrose) required at least 16 weeks to elicit hepatic 
insulin resistance, with no change in peripheral insulin sensitivity.  
Absorbed sucrose (a disaccharide comprising glucose and fructose in a 1:1 ratio) is 
degraded into glucose and fructose, and fructose has been found to be the moiety 
responsible for sucrose-induced insulin resistance (Thresher et al., 2000). For instance, 
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Thorburn et al. (2009) showed that a diet containing 35% fructose produced insulin 
resistance, whereas a diet containing 35% glucose did not. This fact could be explained 
explained based on fructose and glucose bioavailabilities: fructose is predominantly 
metabolized in the liver whereas the main part of an oral glucose load is metabolized in 
peripheral tissues; fructose bypasses the phosphofructokinase rate limiting step in 
glycolysis, potentially resulting in unrestrained production of glycolytic end-products and 
systemic dysregulation and, unlike glucose, fructose is transported into the cell insulin-
independent manner (Laville and Nazare, 2009). Thus, follow-up studies demonstrated that 
fructose was the primary mediator of sucrose-induced impairments in insulin action and 
glucose intolerance in vivo (Pagliassotti, 1996; Thresher et al., 2000). 
The addition of sucrose to either drinking water or rat chow has been shown to 
produce similar changes in the circulating insulin, triglycerides, cholesterol and glucose as 
well as in the body weight.  
High sugars intake is linked to an increased risk of heart disease. Moreover, previous 
studies have shown that high-sucrose feeding in rats lead to the development of cardiac 
dysfunction. (Davidoff et al., 2004; Vasanji et al., 2006; Dutta et al., 2001). Mechanical 
properties of isolated ventricular myocytes from sucrose-fed rats demonstrated 
abnormalities in cardiac contractile performance and calcium hanlding, which are results of 
insulin resistance stage of this model (Vasanji et al., 2006). Sucrose feeding also increased 
systolic blood pressure in rats with increased LV mass but without cardiac fibrosis 
(Sharma et al., 2008). With these evidences, the high sucrose feeding rats may be 
considered an experimental DCM, with similar clinical manifestation of DCM in humans. 
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The general goal of the study is to evaluate the impact of a high-sugar diet (sucrose 
consumption) on the cardiac tissue, as an attempt rat model of (pre)diabetic 
cardiomyopathy with insulin resistance, but lacking sustained/overt hyperglycemia. The 
mechanisms possibly involved in the alterations putatively encountered will be screened.  
To accomplish the main purpose, the following specific aims will be pursued: 
 This experimental model of (pre)diabetes and insulin resistance will be 
characterized in terms of body weight evolution, glycemic profile (fasting and fed glucose 
levels, HbA1c and GTT), insulinemia, insulin tolerance/resistance (ITT and HOMA-IR), as 
well as concerning basic lipid profile (serum Total-cholesterol and TGs levels). The 
expression of cardiac tissue IR-β, PI3K, MAPK and TRB3 will be assessed as a measure of 
possible alterations in some of the main insulin signaling proteins and resistance; 
 The cardiac “(dys)function” and the underlying mechanisms will be assessed by 
measuring blood pressure and heart rate, heart and LV trophism indexes and protein and/or 
mRNA expression of markers of fibrosis, hypertrophy, proliferation, apoptosis, 
angiogenesis, endothelial function, inflammation and oxidative stress, including: TGF-β1, 
procollagen III , CTGF, TSP-1, BNP, Bax, Bcl-2, VEGF, TNF-α, IL-6, ICAM-1, VCAM-
1, iNOS, SOD, HNE and RAGE. This cardiac tissue data will be accompanied with serum 
values of some markers of proliferation, inflammation and redox status: TGF-β, VEGF, IL-
6, IFN-γ, PCR and MDA/TAS. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. MATERIAL AND METHODS 
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1. Animal model and diet 
Experiments were performed on male adult (16 weeks-old) Wistar rats (Charles 
River Laboratories, Barcelona, Spain), weighting 332.9 ± 9.0g at the time of arrival. 
Animals were housed two per cage in the experimental vivarium of the Laboratory of 
Pharmacology and Experimental Therapeutics (IBILI, Faculty of Medicine, University 
of Coimbra) under controlled temperature (22-23ºC) and lighting (12:12-h light-dark 
cycle). On arrival, all rats were given standard chow and water ad libitum. After 1 week of 
acclimatization, animals were randomly divided into two groups (Figure 8): control group 
(n=7), rats continued to receive tap water for drinking; and high-sucrose diet group (HSu) 
(n=8), rats received 35% sucrose (S0389; Sigma-Aldrich) in drinking water for a period of 
9 weeks. All animals were fed standard rat chow (containing 16.1% protein; 3.1% lipids; 
3.9% fibers and 5.1% minerals, (AO4 Panlab, Barcelona, Espanha) ad libitum (with 
exception in the fasting periods). All experiments were conducted according to the 
National and European Directives on Animal Care. 
 
 
 
 
 
 
 
Figure 8. Schematic diagram of study design. GTT, Glucose Tolerance Test; ITT, Insulin Tolerance Test. 
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2. Monitoring of body weight  
The body weight (BW) of each animal was recorded weekly during the experimental 
period, using an analytical balance (KERN CB 6 K1, Germany). 
3. Blood pressure and heart rate assessment 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood 
pressure (MBP) and heart rate (HR) values were obtained using a tail-cuff 
sphygmomanometer LE 5001 (Letica, Barcelona, Spain) in appropriate contention cages, 
and in conscious rats. Before the measurements, the animals were warmed for 10-20 min. 
at 25-30 °C in order to allow the detection of tail artery pulsations and to achieve the pulse 
level ready. BP and HR values were obtained by averaging 8-10 measurements. To 
minimize stress-induced fluctuations in BP, all the rats were adapted to appropriate cages 
and to measurements during at least 2 weeks before the beginning of data collection. The 
same person took the final values in the same peaceful environment between 14:00 h and 
18:00 h. 
4. Animal sacrifice and collection of blood and tissue samples 
The day before the final time, after an overnight fasting period, rats were subjected to 
intraperitoneal anesthesia with a 2 mg/kg BW of a 50 mg/kg pentobarbital (Sigma-Aldrich, 
Portugal) solution and a blood sample was immediately collected by venipuncture from the 
jugular vein into syringes with Heparin-Lithium (Sarstedt, Monovette®) for plasma 
samples, in order to measure fasting glycemia and insulin levels. 
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At the final time (T9), animals were anhetized in the same conditions and blood 
samples were immediately collected by venipuncture from the jugular vein in needles 
without anticoagulant (for serum samples collection). 
The rats were then sacrificed by cervical dislocation, and the heart was immediately 
removed, placed in ice-cold Krebs buffer, carefully cleaned of adherent fat and connective 
tissue, weighted and divided in left and right ventricle. Heart regions were frozen in liquid 
nitrogen and stored at -80ºC, for biochemical, gene expression or Western-blot analysis. 
5. Determination of cardiac trophism indexes 
The heart of each animal, collected as previously described, was weighed and further 
divided in left and ventricles in order to calculate the following ration as cardiac trophism 
indexes: heart weight (HW)/BW and left ventricle weight (LVW)/HW. 
6. Glycemic and insulinemic profile 
6.1. In vivo assays 
6.1.1. Fasting glycemia 
At the end of experimental period, 6-hour fasted rats were tested for estimation of 
blood glucose levels, which was measured in the tail vein using the portable device One 
Touch® UltraEasy® glucometer (Lifescan, Johnson and Johnson, Portugal). 
6.1.2. Glucose tolerance test (GTT) 
Rats submitted to a fasting period of 6-h were administered intraperitoneally (i.p.) 
with a glucose bolus of 2 g/kg BW and the tail vein blood glucose levels were measured in 
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samples taken immediately before the bolus and 30, 60, 90, and 120 min. after, using the 
portable device One Touch® UltraEasy® glucometer (Lifescan, Johnson and Johnson, 
Portugal). The area under the curve (AUC) for the GTT was calculated by using the 
trapezoidal method. 
6.1.3. Insulin tolerance test (ITT) 
The ITT was performed through the i.p. administration of insulin (I9278, Sigma), 
0.75 U/kg BW, in 6-h fasted rats. Blood glucose was monitored in the tail vein blood 
collected immediately before the insulin injection and 15, 30, 45, 60 and 120 min. after, 
using the portable device One Touch® UltraEasy® glucose monitoring system glucometer 
(Lifescan, Johnson and Johnson, Portugal). 
6.2. Ex vivo assays 
6.2.1. Postprandial (Fed) glycemia 
Serum glucose levels were measured using an automatic analyzer (Hitachi 747 
chemistry analyzer, Diamond Diagnostics Inc., Holliston, MA, EUA), standardized for 
clinical data. A glucose oxidase comercial kit (Sigma, St. Louis, Mo, USA) was used. This 
is based on a colorimetric based on a colorimetric enzymatic principle: in presence of 
atmospheric oxygen, glucose is oxidized by glucose oxidase (GOD) to gluconolactone and 
hydrogen peroxide (H2O2). The resulting H2O2 is oxidized in the presence of peroxidase 
(POD), and reacts with phenol and 4-aminophenazone, an oxygen acceptor, originating a 
red quinone-imine chromogen. The color intensity is directly proportional to the 
concentration of glucose present and can be photometrically measured. 
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6.2.2. HbA1c 
HbA1c is the product of non-enzymatic glycation between glucose and free amino 
groups of hemoglobin. As the level of HbA1c is proportional to the level of glucose in the 
blood over a period of two months, it is used to characterize this concentration as an 
indicator of the mean daily blood glucose in recent months. To measure of HbA1c, the 
DCA Vantage latex immunoagglutination method (Siemens Healthcare Diagnostics, 
Barcelona, Spain) was used. This method is characterized by use of specific monoclonal 
antibody for HbA1c mouse. 
For the measurement of total hemoglobin, potassium ferricyanide is used to oxidize 
hemoglobin in the sample to methemoglobin. The methemoglobin then complexes with 
thiocyanate to form thiocyan-methemoglobin, the coloured species measured. The extent 
of color development at 531 nm is proportional to the concentration of total hemoglobin in 
the sample. 
For the measurement of specific HbA1c, an inhibition of latex agglutination assay is 
used. An agglutinator (synthetic polymer containing multiple copies of the immunoreactive 
portion of HbA1c) causes agglutination of latex coated with HbA1c specific mouse 
monoclonal antibody. This agglutination reaction causes increased scattering of light, 
which is measured as an increase in absorbance at 531 nm. HbA1c in whole blood 
specimens competes for the limited number of antibody-latex binding sites causing an 
inhibition of agglutination and a decreased scattering of light. The decreased scattering is 
measured as a decrease in absorbance at 531 nm. The HbA1c concentration is then 
quantified using a calibration curve of absorbance versus HbA1c concentration. The 
percent HbA1c in the sample is then calculated using the following equation: 
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6.2.3. Serum insulin  
Serum insulin levels were quantified by using a rat insulin ELISA (Enzyme-Linked 
Immuno-Sorbent Assay) kit from Mercodia (Uppsala, Sweden) which is a solid phase two-
site enzyme immunoassay. This method is based on the direct sandwich technique, in 
which two monoclonal antibodies are directed against separate antigenic determinants on 
the insulin molecule. In incubation phase, molecules of insulin in sample react with 
peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies fixed in microtiter 
well. Unbound enzyme labeled antibody is removed in washing step. The bound 
conjugated enzyme is detected by reaction with 3,3’,5,5’-tetramethylbenzidine. The final 
step of reaction occurs by adding stop solution acid, which forms a coloured compound 
that can be measured by spectrophotometry. 
6.2.4. Insulin resistance index 
The homeostasis model assessment of insulin resistance (HOMA-IR) index has been 
used as a measure of insulin resistance. This parameter was calculated using the 
Matthews et al. (1985) formula: 
        
                               
    
 
The values used (insulin and glucose) were obtained after an overnight of food 
deprivation, as described in section 4. 
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7. Lipid profile 
Blood was collected to syringes without anticoagulant and centrifuged (730 g, 15 
min. at 4 °C). Serum total cholesterol (Total-c) and triglycerides (TGs) were analyzed on a 
Hitachi 717 automatic analyzer (Roche Diagnostics) using Cholesterol RTU® reagent 
(bioMérieux®, Lyon, France) and the triglycerides kit TG PAP 1000 (bioMérieux®, Lyon, 
France), respectively. These colorimetric methods are based on the application of some 
enzymes, whose final enzymatic chain compound staining intensity is directly proportional 
to the amount of triglycerides and cholesterol in the sample. 
8. Serum markers of inflammatory,angiogenesis and proliferation 
Serum levels of transforming growth factor β-1 (TGF-β1), vascular endothelial 
growth factor (VEGF), interferon-gamma (IFN-γ) and interleukin-6 (IL-6) were measured 
through micro-ELISA sandwich assay, using commercial ultrasensitive Quantikine® 
ELISA kits (R&D Systems,Minneapolis, USA). C-reactive protein (CRP) levels, in serum, 
were also measured by micro-Elisa method using a commercial kit (Alpha Diagnostic 
International, San Antonio, Texas, USA). 
This assay employs the quantitative sandwich enzyme immunoassay technique and 
consists on use a mouse monoclonal antibody, specific for each of the elements to be 
determined, to coat onto the microplate. Standards, controls and samples are pipetted into 
the wells, and the substance to be assayed present in the serum bounds to immobilized 
antibody. In order to remove all unbound substances, washing the wells is carried out. 
Then, an enzyme-linked polyclonal antibody specific for each substance in analysis is 
added to the wells. Following a wash to remove any unbound antibody-enzime reagent, a 
substrate solution is added to the wells. The enzyme reaction yields a blue product that 
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turns yellow when the stop solution is added. The intensity of the colour measured is in 
proportion to the amount of substance to be determined. The sample values are then read 
off the standard curve. 
9. Evaluation of oxidative stress 
9.1. Serum and heart lipid peroxidation  
The measurement of thiobarbituric acid reactive substances (TBARs) is a method to 
determine lipid peroxidation. Malondialdehyde (MDA) is one of the major aldehyde derive 
from the decomposition of lipid peroxides. When subjected to conditions of acidic pH (3.5) 
and high temperature (100 °C), this aldehyde reacts with thiobarbituric acid (TBA) 
originating the adduct (TBA-MDA), a red chromogen, that can be measured 
spectrophotometrically (532 nm) or by fluorescence (excitation λ of 534 nm and λ 
emission 551nm). 
Two hundred micrograms of heart fraction was homogenized in 2 ml of phosphate 
buffer at pH=7.4 with 10 µl solution of antioxidant butylated hydroxytoluene (BHT) in 
acetonitrile, and then centrifuged at 10.000 rpm for 10 minutes at 4 °C, when the 
supernatant was collected to sonicate for 3 minutes. After another centrifugation at 
4000rpm, 4 °C for 15 minutes, the supernatant was collected again, now ready for be 
quantified. 
To quantify the concentration of MDA in the sample, 100 µl of serum, as weel as 
100 µl of tissue, previously collected and homogenized, were used, and a calibration curve. 
The calibration curve was established by preparing a comercial stock solution of 
malondialdehyde-bis-dimethylacetal at concentration of 83.5 mmol/l, from which the 
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standard solutions of known concentrations (0.42, 0.83, 1.67, 2.5, 4.17, 8.3, 16.7 mmol / l) 
were prepared, including the blank sample. 
In a 10 ml tube, 100 µl of sample or distilled water (the blank) or solution (for 
standard samples) were placed. Regardless of the group, 100 µl of BHT dissolved in 
ethanol, 100 µl of catalytic iron trichloride hexahydrate (FeCl3.6H2O) dissolved in distilled 
water, 1.5 ml of glycine-HCl buffer at pH 3.5 and finally 1.5 ml of reagent chromogen, 
TBA were further added. All tubes were placed in the dark at a temperature of 5 °C for 60 
min. The tubes "capped" with glass beads were the kept in water bath at 95-100 °C.  
Thereafter, the tubes were cooled in an ice bath, where samples were extracted with 
2.5 ml of a n-butanol-pyridine (15:1 v/v) solution and 0.5 ml of water distilled. Then, the 
tubes were centrifuged at 1000g for 10 minutes, after which the supernatant was collected 
and the absorbance read at 532 nm. 
9.2. Quantification of serum total antioxidant status (TAS) 
The serum total antioxidant status was quantified using a commercial kit Total 
Antioxidant Status (Randox Laboratories Ltd., UK) and measured on a Hitachi 704 
analyzer. 
This test is based on a colourimetric method, which is formed ferrylmyoglobin, 
which results from reaction of metmyoglobin, a peroxidase, with H2O2. In turn, the 
ferrylmyoglobin reacts with 2,2’-azinobis (3-ehylbenzothiazoline-6-sulfonate) (ABTS), 
resulting a cationic radical (ABTS
•+
), which, due to its blue-green colour, is detected 
spectrophotometrically at 600 nm. The antioxidants presents in the samples cause 
inhibition of this colour production to a degree that is proportional to its concentration. 
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10. Western bloting analysis 
The extracts were obtained from the left ventricle and were homogenized in 1.5ml of 
RIPA lysis buffer (150 mM NaCl; 50 mM Tris-HCl pH=8.0; 5 mM EGTA; 1% Triton X-
100; 0.5% DOC; 0.1% SDS), supplemented with a protease inhibitor cocktail (1 mM 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1 µg/mL chymostatin, 1 µg/mL 
leupeptin, 1µg/mL antipain and 5 µg/mL pepstatin A; Sigma-Aldrich) and centrifuged 3 
times (15500 x g, 15 min., 4ºC).  
The resulting supernatant fraction (corresponding to total extract) was collected and 
total protein concentration was determined using the bicinchoninic acid assay (BCA assay) 
(Smith et al., 1985) and supernatants were stored at -80º C until further use. 
Samples were denatured at 95ºC for 5 min in sample buffer (0.5M Tris-HCl 0.5M 
(pH=6.8), 10% (w/v) SDS, 30% (v/v) glycerol, 0.6M DTT, 0.01% (w/v) bromophenol 
blue), for 6 repetitions and proteins were separated by SDS-polyacrylamide gel 
electrophoresis (190 V), according to Laemmli procedure (Laemmli U., 1970). Ten % 
acrylamide gels were used for all proteins analyzed except for PI3K (≈80 kDa) and IR-β 
(90 kDa) and MAPK (≈38kDa), which were separated using a lower acrylamide 
percentage (7.5%). 
For immunodetection analysis, 25 to 90 µg of total protein were loaded and separated 
by electrophoresis on sodium dodecyl sulfate polyacrylamide gel electrophoresis, 
electroblotted (110V, 90 min.) onto a polyvinylidene difluoride (PVDF) membranes 
(Immobilon PVDF transfer membranes 0.45μm, Millipore, Madrid, Spain) and blocked 
with 1% bovine serum albumin (BSA) in phosphate buffer saline with 0.1% Tween-20 
(PBS-T) for 1 hour at room temperature. Membranes were then incubated with primary 
antibody, overnight at 4ºC The membranes were washed extensively in 0.1% PBS-T and 
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then incubated for one hour at room temperature with adequate alkaline phosphatase 
conjugated secondary antibodies (Table 1). After secondary antibody incubation, 
membranes were washed for one hour in 0.1% PBS-T. To confirm equal protein loading 
and sample transfer blots were reprobed with either rabbit anti-β-actin or mouse anti-
GAPDH. 
After reaction with enhanced chemifluorescence detection reagent (ECF, GE 
Healthcare), immunoreactive bands were revealed by scanning blots using a Fluorescent 
image analyzer Typhoon FLA 900 (GE Healthcare Bio-sciences) imaging system. 
Densitometric analyses were performed using the Image Quant 5.0 software (Molecular 
Dynamics). Results were normalized against β-actin or GAPDH and then expressed as 
percentage of control. 
Table 1. Primary and secondary antibodies used for Western-blot analysis. 
Antibody 
Molecular 
Weight (kDa) 
Loading 
(μg) 
Dilution Reference Company 
Rabbit anti-RAGE ≈55 25 1:1000 Ab-3611 Abcam 
Rabbit anti-HNE - 50 1:1000 393207 Calbiochem 
Rabbit anti-IR-β (C-19) 90 90 1:1000 sc-711 
Santa Cruz 
Biotechnology 
Rabbit anti-p85 Pi3K 80 90 1:1000 4292 
Cell Signaling 
Technology 
     Technology 
Rabbit anti-p38 MPAK 38 90 1250 2507 Biolegend 
Rabbit anti-TNF-α ≈26 75 1:600 Ab6671 Abcam 
Rabbit anti-β-actin 42 - 1:5000 A 5441 Sigma life sciences 
Mouse anti-GAPDH 38 - 1:5000 Ab9484 Abcam 
Goat anti-mouse - - 1:5000 A 3562 Sigma life sciences 
Goat anti-rabbit - - 1:5000 1317 GE Healthcare 
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11. Heart gene expression analysis 
11.1. Total RNA isolation  
The heart was isolated in autopsy and stored in RNA later™ solution (Ambion, 
Austin, TX, USA). Samples were removed from preservation solution and 1200 μL of RLT 
Lysis Buffer were added to proceed with disruption and homogenization for 2 min. at 30 
Hz using TissueLyser (Qiagen, Hilden, Germany). Tissue lysate were processed according 
to the protocol from RNeasy® Mini Kit (Qiagen, Hilden, Germany). Total RNA was 
eluted in 50 μL of RNase-free water (without optional treatment with DNAse). In order to 
quantify the amount of total RNA extracted and verify RNA integrity (RIN, RNA Integrity 
Number), samples were analyzed using 6000 Nano Chip® kit, in Agilent 2100 bioanalyzer 
(Agilent Technologies, Walbronn, Germany) and 2100 expert software, following 
manufacturer instructions. The yield from isolation was from 0.5 to 3 μg; RIN values were 
6.0–9.0 and purity (A260/A280) was 1.8-2.0. 
11.2. Reverse transcription  
RNA was reverse transcribed with SuperScript™ III first-strand synthesis system for 
RT-PCR (Invitrogen, California, USA). One microgram of total RNA was mixed with a 2× 
First-Strand Reaction Mix and a SuperScript™ III Enzyme Mix (Oligo(dT) plus Random 
hexamers). Reactions were carried out in a thermocycler Gene Amp PCR System 9600 
(Perkin Elmer, Norwalk, CT, USA), 10 min. at 25°C, 50 min. at 50°C and 5 min. at 85°C. 
Reaction products were then digested with 1 μL RNase H for 20 min. at 37°C and, finally, 
cDNA eluted to a final volume of 100 μL and stored at -20°C. 
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11.3. Relative quantification of gene expression  
Relative quantification of gene expression was performed using 7900 HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). A normalization step 
preceded the gene expression quantification, using geNorm Housekeeping Gene Selection 
kit for Rattus norvegicus (Primer Design, Southampton, UK) and geNorm software (Ghent 
University Hospital, Center for Medical Genetics, Ghent, Belgium) to select optimal 
housekeeping genes for the study samples (Vandesompele et al., 2002). Real-time PCR 
reactions used specific QuantiTect Primer Assays (Qiagen, Hilden, Germany) with 
optimized primers (Table 2) for TGF-β1 as proliferative markers; BNP, CTGF, TSP-1 and 
Procollagen III as fibrotic/ hypertrophic; VEGF as an angiogenesis marker; ICAM-1, 
VCAM-1, and iNOS as indicator of endothelial lesion; IL-6 and TNF-α as inflammatory 
markers; and Bax and Bcl-2 as apoptotic indicators; Beta (β)-actin (QT00193473) was also 
used as endogenous control with QuantiTect SYBR Green PCR Kit Gene expression 
(Qiagen, Hilden, Germany) according to manufacturer’s instructions. RT-qPCR reactions 
were carried out with 100 ng cDNA sample, primers (50–200 nM) and 1X QuantiTect 
SYBR Green PCR Master Mix. Nontemplate control reactions were performed for each 
gene, in order to assure no unspecific amplification. Reactions were performed with the 
following thermal profile: 10 min. at 95°C plus 40 cycles of 15 s at 95°C and 1 min. at 
60°C. Real-time PCR results were analyzed with SDS 2.1 software (Applied Biosystems, 
Foster City, CA, USA) and quantification used the 2
−ΔΔCt
 method (Livak and Schmittgen, 
2001). 
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Table 2. Primer sequences for real-time RT-PCR. 
Gene Primer sequence 
BAX 
Forward: 5’-CCAAGAAGCTGAGCGAGTGTCTC-3’ 
Reverse: 5’-AGTTGCCATCAGCAAACATGTCA-3’ 
Bcl-2 
Forward: 5’-GGAGCGTCAACAGGGAGATG-3’ 
Reverse: 5’-GATGCCGGTTCAGGTACTCAG-3’ 
BNP 
Forward: 5’-GGGCTGTGACGGGCTGAG GTT-3’ 
Reverse: 5’-AGTTTGTGCTGGAAGTAAGA-3’ 
CTGF 
Forward: 5’-CGTAGACGGTAAAGCAATGG-3’ 
Reverse: 5’-AGTCAAAGAAGCAGCAAACAC-3’ 
ICAM-1 
Forward: 5’-TTCAACCCGTGCCAGGC-3’ 
Reverse: 5’-GTTCGTCTTTCATCCAGTTAGTCT-3’ 
IL-6 
Forward: 5’-ACCACTTCACAAGTCGGAGG-3’ 
Reverse: 5’-ACAGTGCATCATCGCTGTTC-3’ 
iNOS 
Forward: 5’-CAGAAGCAGAATGTGACCATCAT-3’ 
Reverse: 5’-CGGAGGGACCAGCCAAATC-3’ 
Procollagen typeIII 
Forward: 5’-5’-GGTCACTTTCACTGGTTGACGA-3’ 
Reverse: 5’-TTGAATATCAAACACGCAAGGC-3’ 
SOD 
Forward: 5’-GACAAACCTGAGCCCTAACGG-3’ 
Reverse: 5’-CTTCTTGCAAACTATG-3’ 
TGF-β1 
Forward: 5’-ATACGCCTGAGTGGCTGTCT-3’ 
Reverse: 5’-TGGGACTGATCCCATTGATT-3’ 
TNF-α 
Forward :5’-CACGCTTTCTGTCTACTGA-3’ 
Reverse 5’-GGACTCCGTGATGTCTAAGT-3’ 
TSP-1 
Forward :5’-CTTTGCTGGTGCCAAGTGTA-3’ 
Reverse: 5’-CGACGTCTTTGCACTGGATA-3’ 
TRB3 
Forward:5’-TGATGCTGTCTGGATGACAA-3’ 
Reverse: 5’-GTGAATGGGGACTTTGGTCT-3’ 
VCAM-1 
Forward: 5’-GAAGCCGGTCATGGTCAAGT-3’ 
Reverse: 5’-GACGGTCACCCTTGAACAGTTC-3’ 
VEGF 
Forward: 5’-GAGAATTCGGCCCCAACCATGAACTTTCTGCT-3’ 
Reverse: 5’-GAGCATGCCCTCCTGCCCGGCTCACCGC-3’ 
12. Statistical Analysis 
Results were expressed as means ± standard errors of the mean (S.E.M.) and % of 
the Control, as indicated. Comparisons between groups were analysed by unpaired 
Student´s t-test, using GraphPad Prism software, Version 5.0. Differences were considered 
to be significant at P <0.05. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. RESULTS 
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1. Metabolic characterization of animal model 
1.1. Evolution of body weight 
Body weight (BW) was monitored during the 9 weeks of treatment. The HSu-treated 
rats showed a BW profile similar to that of the control animals (Figure 9). 
 
 
 
 
 
 
1.2. Glycemic profile  
1.2.1. Fasting and fed glycemia  
 
 
   
 
 
 
 
Figure 10. Fasting (A) and fed (B) glycemia values at the final time (9 weeks of treatment). Data are 
expressed as means ± SEM; n=7 per group. *p < 0.05 vs Control. 
 
Figure 9. Body weight evolution of the Control and HSu groups throughout the 9 weeks of treatment. Values 
are expressed as mean ± SEM; n=7 for Control and  n=8 for HSu. 
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There was no significant difference in fasting blood glucose between the two groups 
(102.90 ± 6.98 vs 96.71 ± 4.49 mg/dL) (Figure 10A); however, in a fed state, glycemia was 
significant elevated for the HSu group compared to the Control one (162.90 ± 26.54 vs 
126.80 ± 13.56 mg/dL; p<0.05) (Figure 10B). 
1.2.2. Glycated hemoglobin (HbA1c) 
Concerning HbA1c, a slight but significantly increased value was noted in the HSu 
group when compared with the Control (Figure 11).  
 
 
 
 
 
 
1.2.3. Glucose tolerance test (GTT) 
Basal blood glucose concentrations were similar in Control and HSu groups. After 15 
min of glucose injection, both groups achieved the maximum blood glucose level. 
However, 60 min. after of glucose stimulation, the HSu-treated group showed significantly 
increased blood glucose levels when compared with those of the Control group (215.50 ± 
19.64 vs 159.00 ± 5.83 mg/dl; p<0.05). This difference persisted until the 120 min., when 
the blood glucose concentrations returned to the basal levels in the Control group, but 
remained significantly higher in the HSu-treated group (168.80 ± 10.64 vs 121.40 ± 3.69 
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Figure 11. Glycated hemoglin (HbA1c) values in the Control group and HSu-treated rats. Data are expressed 
expressed as means ± SEM; n=7 for Control and n=8 for HSu. *p < 0.05 vs Control. 
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Figure 12. Glucose tolerance test (GTT) was performed during the last week of treatment. (A) Blood glucose 
levels at baseline and after i.p. injection of glucose (2 g/kg BW) at 15, 30, 60 and 120 min in Control and 
HSu groups. (B) Area under the curve (AUC) of total blood glucose after injection of glucose. Data are 
expressed as means ± SEM; n=6 per group. *p < 0.05; **p<0.01 versus Control. 
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Figure 13. Serum insulin levels after 9 weeks of treatment. Data are expressed as mean ± SEM; n=5 for 
Control and n=3 for HSu. ***p < 0.001 versus Control. 
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mg/dL; p<0.01) (Figure 12A). Figure 12B represents the area under the curve (AUC) of 
GTT, which expresses blood glucose bioavailability, thus confirming the significantly 
(p<0.05) impaired blood glucose tolerance in the HSu group vs Control. 
 
 
 
 
 
 
 
 
1.3. Insulinemic profile and insulin tolerance/resistance 
1.3.1. Fasting insulin levels 
Serum insulin concentration in HSu-treated rats was significantly elevated when 
compared with the Control rats (10.83 ± 1.00 vs 3.74 ±1.84 µg/L; p<0.001) (Figure 13). 
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1.3.2. Insulin tolerance test (ITT)  
After sucrose consumption during 9 weeks, insulin tolerance was assessed by the ITT 
(Figure 14). The blood glucose levels 120 min. after insulin injection were significantly 
higher in the HSu group than in the Control one (63.86 ± 14.78 vs 37.17 ± 7.03 mg/dL; 
p<0.01).  
 
 
 
 
 
 
 
 
1.3.3. HOMA-IR index  
HOMA-IR index was also calculated as an additional measure of insulin resistance 
(Figure 15), using glucose and insulin levels after a fasting state. Significantly higher 
(P<0.01) HOMA-IR values were observed in the HSu- treated group when compared to the 
Control. 
 
 
 
 
 
Figure 14. Insulin tolerance test (ITT) was performed during the last week of treatment. Blood glucose levels 
at baseline and after i.p. injection of insulin (0.75 U/kg BW) at 15, 30, 45, 60 and 120 min. in Control and 
HSu groups. Data are expressed as mean ± SEM; n=7 for Control and n=6 for HSu. **p<0.01 versus Control. 
Figure 15. HOMA-IR index in Control and HSu groups. Data are expressed as mean ± SEM n=5 for Control 
and n=3 for HSu. **p<0.01 vs Control. 
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2. Heart insulin signaling/resistance 
2.1. Cardiac IR-β expression 
No differences were observed on cardiac IR-β expression after 9 weeks of sucrose 
consumption (Figure 16). 
 
 
 
 
 
 
 
 
2.2. Cardiac PI3K and MAPK expression 
 
  
 
 
 
 
 
 
 
Figure 17. Cardiac PI3K and MAPK expression in the Control and HSu-treated rats. Representative 
Western-blot bands are shown on top of bars. GAPDH was used as the internal control. Results are expressed 
as percentage of the control and expressed as means ± SEM. n=3 for Control and n=4 for HSu. 
 
Figure 16. Cardiac IR-β expression in the Control and HSu-treated  rats. Representative Western-blot bands 
are shown on top of bars. β-actin was used as the internal control. Results are expressed as percentage of the 
control and presented as means ± SEM. n=3 for Control and  n=4 for HSu. 
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The PI3K and MAPK contents, proteins involved in the insulin signaling cascade, 
were also analyzed. The Control and HSu-treated rats presented identical PI3K and MAPK 
expression in the heart tissue (Figure 17A and B). 
2.3. Cardiac TRB3 mRNA expression 
TRB3 has been implicated in heart insulin resistance and the mRNA expression in 
the cardiac tissue was assessed as an additional measure of heart insulin resistance. There 
was no significant difference on the heart TRB3 mRNA expression between groups 
(Figure 18). 
 
 
 
 
 
 
 
 
 
 
Figure 18. Cardiac TRB3 mRNA expression in the Control and HSu-treated rats. β-actin was used as the 
internal control. Results are expressed as percentage of the control and means ± SEM; n= 5 per group. 
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3. Lipid profile 
3.1. Serum triglyceride and total-cholesterol levels 
The HSu group showed elevated serum triglyceride contents compared to the Control 
(Figure 19A), while no significant difference was observed on total-cholesterol 
concentration between the two groups (Figure 19B).  
 
 
 
 
 
 
 
4. Cardiac “(dys)function” 
4.1. Blood pressure and heart rate 
No significant differences were found in systolic, diastolic and mean blood pressure, 
as well as in heart rate, between the two groups at the final time (Table 3). 
Parameter 
Control 
(n=7) 
HSu 
(n=8) 
SBP (mmHg) 122.0 ± 1.8 121.6 ± 1.1 
DBP (mmHg) 100.1 ± 1.5 98.4± 1.3 
MBP (mmHg) 108.8 ± 1.3 109.8 ± 1.2 
Heart Rate (beats/min) 356.7 ± 1.0 368.9 ± 8.1 
Data are expressed as mean ± SEM. 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure.  
Table 3. Blood pressure and heart rate values in Control and HSu rats after 9 weeks of experiment.  
 
Figure 19. Serum triglycerides (A) and total-cholesterol (B) levels in Control group and HSu-treated groups 
after 9 weeks of treatment. Data are expressed as mean ± SEM, n=7 per group. *p<0.05 vs Control.  
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4.2. Heart and LV trophism 
The parameters of cardiac trophism were evaluated at the final time of experiment. 
Despite an elevated value of heart weight in the HSu-treated rats versus Control, similar 
values between groups were encountered. However, LV weight and LVW/BW were 
significantly higher in the HSu-treated rats versus the Control ones (p<0.01 and p<0.001, 
respectively) (Table 4). 
Parameter Control HSu 
Heart (g) 0.89 ± 0.09 1.10 ± 0.02* 
LV (g) 0.45 ± 0.00 0.53 ± 0.02*** 
Heart / BW (g/kg) 2.14 ± 0.23 2.62 ± 0.07 
LV / BW (g/kg) 1.07 ± 0.02 1.28 ± 0.04** 
Data are expressed as mean ± SEM, *P<0.05; ** P<0.01; ***P<0.001 versus Control. 
LV, left ventricular mass, BW, body weight. 
5. Markers of fibrosis and hypertrophy/proliferation 
5.1. Serum TGF-β1 levels 
There was no significant difference in serum TGF-β1 levels between the two groups 
at the final time of experiment (Figure 20). 
 
 
 
 
 
 
Table 4. Parameters of cardiac trophism in Control and HSu rats at the final time of study (9 weeks). 
Figure 20. Serum TGF-β1 levels in the Control and HSu-treated rats. Data are expressed as mean ± SEM; 
n=7 for Control and n=8 for HSu group. 
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5.2. Cardiac mRNA expression 
To assess the influence of sucrose consumption on heart proliferation, hypertrophy 
and fibrosis, the following proteins were evaluated: TGF-β1, TSP-1, pro-collagen III, 
CTGF, BNP. No significant changes were encountered concerning the cardiac mRNA 
expression of TGF-β1, TSP-1, pro-collagen III and CTFG (Figure 21A and B). However, 
in the heart tissue, significantly BNP gene overexpression was found in HSu-treated 
animals (p<0.01) (Figure 21C). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Cardiac TGF-β, TSP-1, Pro-collagen III (A), CTGF (B) and BNP (C) mRNA expression at the 
final time (9 weeks) in the Control and HSu-treated rats. Β-actin was used as the internal control. Data are 
expressed as percentage of the control and expressed as means ± SEM; n=5 per group. **P<0.01 versus 
Control. 
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6. Markers of apoptotic machinery 
Concerning the apoptotic machinery markers, no changes were encountered in the 
heart tissue for BAX and Bcl-2 mRNA expression in the HSu rats vs the Control ones 
(Figure 22). 
 
 
 
 
 
 
7. Marker of angiogenesis and endothelial lesion 
7.1. Serum VEGF concentrations 
The HSu-treated rats showed significantly (p<0.05) elevated values of serum VEGF 
vs the Control group (Figure 23). 
 
 
 
 
 
Figure 23. Serum vascular endothelial growth factor (VEGF) in the Control and HSu-treated rats. Data are 
expressed as mean ± SEM; n=7 for Control and n=8 for HSu group. *P<0.05 vs Control. 
Figure 22. Cardiac BAX and Bcl-2 mRNA expression at the final time (9weeks) in the Control and HSu-
treated rats. β -actin was used as the internal control. Results are expressed as percentage of the control and 
expressed as means ± SEM; 5 per group. 
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7.2. Cardiac mRNA expression 
VEGF, iNOS, ICAM-1 and VCAM-1 gene expression was assessed as markers of 
putative changes on angiogenesis and endothelial lesion. Unchanged values were found for 
VEGF (Figura 24A), iNOS (Figura 24B), ICAM-1 and VCAM-1 (Figure 24C) mRNA 
expression, despite a trend to higher values for all the genes vs Control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Cardiac VEGF (A), iNOS (B), ICAM-1 and VCAM-1 (C) mRNA expression at the final time (9 
weeks) in the Control and HSu-treated rats. β-actin was used as the internal control. Results are expressed as 
percentage of the control and expressed as means ± SEM; 5 per group.  
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8. Inflammatory mediators  
8.1. Serum concentrations 
There were no differences in serum IL-6 and IFN-γ values between the two groups at 
the final time (Figure 25A and B). Concerning the serum CRP levels, a statistically 
significant decrease (p<0.01) was observed in the HSu group when compared with the 
Control (Figure 25C). 
 
 
 
 
 
 
 
 
 
 
8.2. Cardiac IL-6 and TNF-α mRNA expression 
The influence of sucrose on the heart IL-6 and TNF-α was also assessed. Concerning 
the sucrose-treated rats, a trend to decreased TNF-α mRNA expression was observed but 
the values did not read statistical significance (Figure 26). 
 
Figure 25. Serum IL-6 (A), IFN-γ (B) and CRP (C) levels in the Control and HSu-treated rats. Data are 
expressed as mean ± SEM; n=7 for Control and n=8 for HSu group. **P<0.01 versus Control. 
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8.3. Cardiac TNF-α protein expression 
TNF-α adducts were detected in a broad range of different molecular weight. 
Although no significant differences were observed for each adduct between groups, the 
TNF-α content showed a trend to increase in HSu-treated rats (Figure 27). 
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Figure 26. Cardiac  mRNA expression of inflammatory marker at the final time (9 weeks) in the Control and 
HSu-treated rats. β-actin was used as the internal control. Results are expressed as percentage of the control 
and expressed as means ± SEM; n= 5 per group. 
Figure 27. Cardiac TNF-α expression in the Control and Hsu-treated rats. Representative Western-blot bands 
are shown on top of bars. β-actin was used as the internal control. Results are expressed as percentage of the 
control and expressed as means ± SEM. n=3 for Control and n=5 for Hsu. 
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9. Redox status 
9.1. Serum and heart lipid peroxidation (TBARS) 
Malondialdehyde concentrations were evaluated in serum and cardiac tissue at the 
end of experiment. No differences were found between groups; however, both in serum 
and cardiac tissue MDA levels showed the same profile, with a trend trend to increased 
values in the HSu-treated rats vs the Control ones (Figure 28A and B). 
 
 
 
 
 
 
 
 
9.2. Serum total antioxidant status (TAS) 
The value of total antioxidant capacity (TAS) was significantly higher (P<0.05) in 
the HSu group when compared with the Control (Figure 29). 
 
 
 
 
Figure 28. Malondialdehyde (MDA) concentrations in serum (A) and in the cardiac tissue (B). Data are 
expressed as mean ± SEM, n=7 for Control and n=8 for HSu group. 
Figure 29. Serum total antioxidant status (TAS) in the Control and HSu-treated rats. Data are expressed as 
mean ± SEM; n=7 for Control and n=8 for HSu group. *P<0.05 versus Control. 
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9.3. Serum TBARS/TAS ratio 
No significant differences were encountered for MDA/TAS between the groups 
(Figure 30). 
 
 
 
 
 
9.4. Cardiac HNE expression 
HNE adducts were detected in a broad range of different molecular weights. Only 
HNE-adduct weighing ≈30 kDa was significantly (p<0.05) decrease in the HSu group 
(Figure 31C). However, although no significant difference were observed in HNE adducts 
with weight ≈70 kDa and ≈ 40 kDa between Control and HSu rats, both showed an 
identical profile to that found for the HNE- adduct ≈30 kDa, with a trend to decrease in the 
HSu-treated group (Figure 31A and B). 
 
 
 
 
 
 
 
Figure 30. MDA/TAS ratio in the Control and HSu-treated rats. Data are expressed as mean ± SEM; n=7 for 
Control and n=8 for HSu group. *P<0.05 versus Control. 
 
Early cardiac effects of a high-sucrose diet in a rat model of prediabetes 
2012 
 
82 
Control HSu
0
50
100
150
*
C
H
N
E
 e
x
p
re
s
s
io
n

 3
0
 k
D
a
(%
 o
f 
c
o
n
tr
o
l)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control HSu
0
50
100
150
A
H
N
E
 e
x
p
re
s
s
io
n

 7
0
 k
D
a
(%
 o
f 
c
o
n
tr
o
l)
Control HSu
0
50
100
150
B
H
N
E
 e
x
p
re
s
s
io
n

 4
5
 k
D
a
(%
 o
f 
c
o
n
tr
o
l)
Figure 31. Cardiac HNE expression in the Control and HSu-treated rats. Representative Western-blot bands 
are shown on top of bars. GAPDH was used as the internal control. Results are expressed as percentage of 
the control and expressed as means ± SEM. n=3 for Control and n=4 for Hsu. *P<0.05 versus Control.  
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9.5. Cardiac RAGE expression 
A significant decrease (p<0.01) of RAGE expression was observed 9 weeks after 
sucrose consumption vs the untreated Control rats (Figure 32). 
. 
 
 
 
 
 
9.6. Cardiac SOD mRNA expression 
Concerning the sucrose treatment, a remarkable increment (p<0.05) in cardiac SOD 
mRNA expression was observed (Figure 33).  
 
 
 
 
 
Figure 32. Cardiac RAGE expression in the Control and HSu-treated rats. Representative Western-blot 
bands are shown on top of bars. β-actin was used as the internal control. Results are expressed as percentage 
of the control and expressed as means ± SEM. n=3 for Control and n=5 for HSu. **P<0.01 versus Control. 
 
Figure 33. Cardiac SOD mRNA expression at the final time (9weeks) in the Control and HSu-treated rats. 
GAPDH was used as the internal control. Results are expressed as percentage of the control and expressed as 
means ± SEM. n=3 for Control and n=5 for HSu. *P<0.05 versus Control. 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI. DISCUSSION 
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The global prevalence of DM is increasing very fast; currently the number of diabetic 
people is over 300 million and expected to reach close to 500 million within 20 years 
(Silink, 2009; Acar et al., 2011). Cardiovascular diseases are responsible for three quarters 
of the deaths among this population (Khavandi et al., 2009). Although CAD is very 
common, HF is also a major cause of mortality and morbidity in patients with DM (Cohen-
Solal et al., 2008). In addition, diabetic individuals are under increased risk for HF 
development after adjusting concomitant risk factors, such as hypertension and CAD 
(Murarka and Moahed, 2010; Bertoni et al., 2003, Boundina and Abel, 2010). The 
Framingham study, United Kingdom Prospective Diabetic Study and Euro Heart Failure 
Survey all suggested that the presence of diabetes may independently increase the risk of 
developing HF. Up to 75% of patients with unexplained idiopathic dilated cardiomyopathy 
were found to be diabetic (Bertoni et al., 2003). 
The natural history of prediabetes predicts that a significant number of persons with 
the condition progress to diabetes in the long run (Colagiuri, 2011). The most common 
definition of prediabetes refers to IGT and/or IFG, which were conceived to define 
categories of glycemia associated with an increased risk of developing diabetes 
(Buysschaert and Bergman, 2011). In the earlier stage, i.e. in prediabetic state, T2DM is 
almost or even totally asymptomatic, complicating its diagnosis. However, many of 
complications associated with the disease, specifically the cardiovascular ones, appear in 
that phase. Furthermore, late diagnosis is associated with a worsening of the disease and, 
consequently, evolution of its complications. Thus, early screening of patients with 
subclinical cardiac alterations is useful to prevent the development of diabetic 
cardiomyopathy and, therefore, reduce heart disease progression. This need is even more 
important when considering that the prevalence of children and adolescent diabetes is also 
increasing, particularly due to premature obesity. 
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An understanding of the cellular effects of these metabolic disturbances on 
cardiomyocytes in the prediabetic state should be useful in predicting the structural and 
functional cardiac consequences. The problem lies in our ability to dissect away 
confounding variables such as concomitant obesity, dyslipidemia, hypertension, and 
proinflammatory and prothrombic states. All of the confounding variables listed, which are 
components of metabolic syndrome, are commonly present in persons with prediabetes 
(Ferrannini et al., 2011; Grundy, 2012).  
Furthermore, the discussion of whether the glucose or the insulin resistance is per se, 
or both, the driving forces for the cardiovascular and the cardiac changes starting before 
the diagnosis, is also relevant. Insulin exerts multiple effects in the heart that collectively 
have a beneficial effect on myocardial substrate metabolism and cardiac function. 
Myocardial insulin resistance accompanies cardiac dysfunction in diabetes-related heart 
disease (Ouwens and Diamant, 2007). Interventions aimed at ameliorating myocardial 
insulin sensitivity have indicated beneficial effects on insulin sensitivity and cardiac 
function in rodent models (Abel, 2005) and may constitute a major therapeutic target in the 
battle against diabetes-related heart disease. Thus, in a state of normoglycemia and insulin 
resistance with hyperinsulinemia, the relative role of glucose and of insulin remains to be 
determined. Insulin resistance is a risk factor of left ventricular dysfunction and HF, and is 
one of the hallmarks of type 2 diabetes (Doehner et al., 2005; Dinh et al, 2011; Stahrenberg 
et al., 2010). However, despite whole body hyperinsulinemia and hyperglycemia, the 
diabetic heart relies almost entirely on FA utilization at the expense of glucose (Carley and 
Severson, 2005). This change in substrate utilization has been described in rodent models 
as well as in humans and can be largely attributed to nutrition of excessive fat containing 
food (Dirkx et al., 2011). Rodents can be made diabetic by prolonged periods of exposure 
to a high fat diet (Bugger and Abel, 2011). 
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To elucidate whether the alteration at cardiac level are already present in prediabetic 
stage, and the underlying mechanisms, we must chose an animal model that presents with 
relatively minor metabolic abnormalities, consistent with prediabetic insulin resistance in 
humans (Pagliassotti et al., 1996; Podolin et al., 1998), and that mimics early stages of type 
2 diabetes, without other complicating factors that could lead to cardiac events (e.g. obesity 
and hypertension). Experimental support is limited with most work focusing on chemically 
induced type 1 models of the disease that ultimately represent an extreme of the metabolic 
profile (rarely encountered in clinical practice) or type 2 models burdened with other 
element(s) of the metabolic syndrome and, thus, the evidence is scarce regarding the 
mechanisms involved in cardiomyopathy in this stage of disease. Therefore, animal models 
of prediabetes could help in the understanding of the events leading to the appearance of 
clinical symptoms.  
The high-sucrose diet rat as a model of prediabetes/insulin resistance 
In agreement to the previous topics, we decided to choose the high-sucrose diet rat as 
a model of prediabetes to evaluate the insulin resistance induced-cardiac dysfunction, 
consisting of 9 weeks of 35% sucrose diet, according to previous studies of Ribeiro et al. 
(2005) and Conde et al. (2011). The insulin resistance described in this animal model is 
associated with glucose intolerance, increased serum insulin concentration 
(hyperinsulinemia) and decreased insulin sensitivity, as described by other authors 
(Kanazawa et al., 2003; Ribeiro et al., 2005; Conde et al., 2011; Sumiyoshi et al., 2011). 
First of all, concerning the metabolic effects of this diet, we must clarify that we 
supplemented a standard non purified diet with a sucrose solution that replaces water in the 
diet. Although the main aim was to assess the effect of adding sucrose to the diet, if the rest 
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of the diet remains constant, the percentage of total energy contributed by components 
other than the added sugar decreases proportionately and there may be an increase in total 
energy intake. Thus, higher energy intakes may also have contributed to differences 
between the HSu and Control groups other than sucrose per se. Animals were given ad 
libitum access to food and drink, so they may consume different amounts of energy, which 
may also confound and influence the response to the diet.  
Our data demonstrate that sucrose consumption induced no significant changes on 
body weight, which was unchanged compared to the Control rats. These results indicate 
that insulin resistance produced in this model is, at least initially, independent of the overt 
obesity, which is consistent with previous studies (Kanazawa et al., 2003). On the other 
hand, Song et al. (2007), showed higher body weight and greater body weight gain in HSu 
rats compared with Control during 16 week of exposure. 
It is important to note the fact sucrose is a disaccharide that consists of 50:50 of 
glucose and fructose that undergo different metabolic pathways after absorption from the 
small intestine. The higher postprandial/fed glycemia values can be explained by the 
glucose availability resultant from both sucrose and diet. On the other hand, the rise in 
glucose level can partly explain the large increase in postprandial insulin level on this diet. 
However, we were unable to evaluate serum insulin levels in a postprandial/fed situation. 
After absorption from the small intestine, fructose is primarily taken up by the liver, 
whereas glucose is metabolized by all cells in the body. Although fructose is absorbed 
more slowly than glucose, it is more readily metabolized because cellular uptake and the 
early steps of fructose metabolism differ markedly from those of glucose. Unlike glucose, 
fructose has only a modest effect on insulin action and does not require the presence of 
insulin to access to the intracellular compartment. Once inside the cell, fructose is very 
rapidly converted to fructose-1-phosphate. This phosphorylation bypasses the early rate-
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limiting step of insulin-stimulated transport, which glucose must undergo. Thus, fructose is 
more lipogenic than glucose and it could potentially modify fatty acids balance in very 
LDL (VLDL) and has harmful effects like hiperlipidemia or insulin resistance. By this 
way, several evidences suggest that fructose is the primary nutrient mediator of sucrose-
induced hypertriglyceridemia, insulin resistance and glucose intolerance (Thresher et al., 
2000; Gadja et al., 2007).  
Because of the preferential entry of fructose into lipogenesis, HSu shown increased 
TG levels, which would increase its deposition in adipose tissue, liver and muscle, 
eventually resulting in impaired insulin signaling and dyslipidemia, increasingly associated 
with proatherogenic conditions. Other factors can contribute to reduced insulin sensitivity 
such as decreased mitochondrial fatty acid oxidation and the accumulation of hepatic 
DAG, which in turn inhibited insulin signaling via activation of PKC-ζ (Dekker et al., 
2010). On the other hand, dietary glucose increases serum glucose and insulin 
concentrations in the postprandial state (Shaeffer et al., 2009).  
Concerning the effects on glycemic profile, our results demonstrate that no 
differences on plasma glucose in the fasted state, but a significant increase in a 
postprandial state in the HSu-treated rats versus Control ones. These finding have also 
been reported by others in rats and humans (Hulman and Falkner 1994; Daly et al., 1998). 
Furthermore, some authors stated that diet-induced insulin resistance is characterized by 
fasting normoglycemia (Thresher et al., 2000; Wright et al., 1999). The higher postprandial 
glucose response found in the HSu group might be explained by the large amount of 
available glucose from both sucrose and starch on this diet.  
Previous studied demonstrated that sucrose consumption produces insulin resistance 
in rats (Santuré et al., 2002; Pagliassotti et al., 1996; Podolin, 1998). After 9 weeks of 
sucrose consumption, insulin resistance was confirmed by GTT and ITT. Therefore, the 
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GTT showed significantly increase blood glucose levels in the HSu animals at 60 min. 
after glucose stimulation, indicating the impaired glucose tolerance. This profile was 
confirmed by the higher AUC value of GTT found in the HSu-treated rats. Similarly, ITT 
revealed impaired insulin sensitivity since 120 min. after insulin injection the HSu rats had 
significantly higher blood glucose levels than those found in the Control animals. The 
profile of insulin resistance was reinforced by the elevated HOMA-IR.  
 In this model, a hyperinsulinemia state was observed (increased levels of serum 
insulin). Thus, HSu-evoked glucose tolerance might be attributed to peripheral insulin 
resistance, as a compensatory hyperinsulinemia is observed in this group compared to the 
Control. In fact, T2DM is recognized as a progressive disorder, which is associated with 
diminishing pancreatic function over time. However, in an early stage, as may occur after 9 
weeks of high sucrose intake, the presence of insulin resistance must be compensated by 
hyperinsulinemia to maintain normoglycemia. It has also been observed that in those 
individuals who develop diabetes, a progressive loss of the insulin secretory capacity of β-
cells appears to begin years before the clinical diagnosis (Cefalu, 2006). Furthermore, a 
considerable proportion of whole-body insulin-stimulated glucose uptake is dependent 
upon the hepatic insulin-sensitizing substance (HISS) in a pathway mediated by the hepatic 
parasympathetic nerves (HPNs) and, according to Ribeiro et al. (2005), a high-sucrose diet 
leads to insulin resistance by rapid impairment of such pathway. 
Elevated serum triglycerides content were observed in HSu-treated rats, which is 
consistent with many other reports (Kanazawa et al., 2003; Cao et al., 2007; Sumiyoshi et 
al., 2006) and may be a result from of de novo lipogenesis, the enhanced rate of hepatic 
triglyceride synthesis and the decrease in peripheral clearance (Suzuki et al., 2004). In this 
study, sucrose consumption do not induce higher serum cholesterol, which is in agreement 
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with Sumiyoshi et al. (2006) that found no increment in total cholesterol in mice fed high 
sucrose diet for 55 weeks. 
Thus, our animal model, consisting of a 35% sucrose diet during 9 weeks of 
treatment, is characterized by a fasting normoglycemia, impaired glucose tolerance, 
accompanied by hyperinsulinemia and impaired insulin tolerance (or insulin resistance), 
together with hypertriglyceridemia, but without obesity. 
Several studies have investigated alteration in insulin signaling in T2DM subjects 
and in animal model of insulin resistance. As was above reviewed, impaired cardiac insulin 
signaling may be a key mechanism underlying the myocardial dysmetabolic profile. 
Furthermore, previous studies have shown that cardiac dysfunction induced by high-fat 
diet is associated with altered myocardial insulin signaling (Ouwens et al., 2005). 
However, data about insulin-mediated cardiac effect or concerning the development of 
insulin insensitivity, as well related with the molecular aspects of cardiac insulin signaling 
are lacking in our model. 
Insulin resistance in the heart is characterized by impaired PI3K/Akt signaling. 
Hence, we looked to the basal expression levels of proteins involved in insulin signaling 
and found no differences between groups on cardiac insulin receptor β, PI3K and MAPK. 
Concerning the insulin receptor, this result is consistent with Pagliassotti et al. (2002) that 
found that sucrose feeding did not lead to reduction of insulin receptor protein levels in 
liver. However, insulin stimulation of tyrosine phosphorylation of IRS proteins, association 
of IRS proteins with p85 subunit of PI3K and PI3k activity were reduced in HSD versus 
STD. One of the major limitations of our study concerning this topic is the lack of 
evaluation of the activity and phosphorylation of each protein involved in insulin signaling, 
which would require an exogenous insulin stimulation prior to sacrifice. Further studies 
should complete the information now obtained. 
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We also analyzed the heart MAPK expression and TRB3 mRNA expression. TRB3 
is a member of Mammalian tribbles homologs (TRB) protein family which, recently, was 
considered to be a critical mediator for insulin resistance which is implicated in DCM, 
thus, emerged our interest in the gene expression evaluation. Our result showed no 
differences in MAPK expression as well in TRB3 mRNA expression between HSu and 
Control group. These results may suggest that TRB3 is not involved in sucrose-induced 
prediabetic state. 
Concerning other aspects related with the cardiac performance, there was no 
significant difference in blood pressure and heart rate at the end of experiment between the 
high-sucrose diet rats and the control ones, indicating that the ingestion of sucrose during 9 
weeks, at least at this concentration (35%), was not sufficient to cause impact on this 
aspect. This appears to contradict previous studies in which inducing insulin resistance 
with a high-sugar diet led to a rise in blood pressure in different rats strains (Hwang et al., 
1987; Reaven and Ho, 1991), which seem to be mediated by the activation of the 
sympathetic nervous and rennin-angiotensin systems (Freitas et al., 2007). Other 
investigators have also failed to show any hypertension when blood pressure was directly 
recorded from an intra-arterial catheter in fructose-fed rats not acutely restrained (Brands et 
al., 1994). Therefore, these findings suggest that insulin resistance can be induced by a 
high-sucrose diet in rats without causing hypertension or significant alterations in heart 
rate.  
As summary, our model is a model of prediabetes/insulin resistance, characterized by 
a fasting normoglycemia, impaired glucose tolerance, hyperinsulinemia, insulin resistance, 
together with hypertriglyceridemia, which could be a useful tool to evaluate the impact on 
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the cardiac tissue and the existence of cardiomyopathy, independently of other 
confounding factors, such as hypertension and obesity. 
Cardiac impact of prediabetes/insulin resistance using a HSu-diet rat 
model 
Diabetic Cardiomyopathy is globally defined as myocardial structural or functional 
abnormalities in the absence of hypertension, CAD and valvular heart disease. DCM is 
frequently seen in the asymptomatic diabetic patients and, thus, screening the disease at the 
earliest stage of development is important for long-term prognosis and prevention of the 
progression to congestive HF. DCM has been a poorly understood disease and the 
underlying mechanisms are not completely elucidated. Development of DCM includes 
complex and multifactorial pathophysiological mechanisms. Common pathological 
changes of diabetic heart are myocyte hypertrophy, interstitial fibrosis and increase in 
contractile protein glycosylation. As a result of these changes, diastolic compliance 
decrease, ventricle hypertrophies and, in advanced stages, systolic functions may worsen 
(Murarka and Movahed, 2010; Turan et al., 2011; Voulgari et al., 2010; Khullar et al., 
2010; Dobrin et al., 2010; Tarquini et al., 2011; Boudina and Abel, 2010). 
The existence of earlier cardiac changes in prediabetes has been suggested, but the 
human studies, and even the animal models, are usually limited because of the coexistence 
of other perturbations. In our model of prediabetes/insulin resistance, the existence of 
earlier cardiac changes was not previously reported and, thus, a larger evaluation of the 
mechanisms putatively involved was chosen. Considering the amount of different 
pathways suggested as contributors for the pathophysiological mechanisms of human 
DCM, we choose to screen some of the aspects putatively implicated, evaluating some 
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serum markers and some cardiac tissues proteins and genes, since the early modifications 
could be all and none in a model previously tested, but notoriously with other features than 
the most common HSu-diet model. 
Cardiac fibrosis and hypertrophy are the two major structural changes associated 
with cardiac dysfunction inherent to DCM, and may occur independently of hypertension. 
Cardiomyocyte hypertrophy as well as subsequent apoptosis and focal myocardial fibrosis 
are structural hallmarks of DCM and functionally manifest as defective cardiac 
contractility (Chen et al., 2000). Previous studies have shown that cardiomyocyte 
hypertrophy in diabetes is regulated at the transcriptional level (Hileeto et al., 2002; Chen 
et al., 2003; Farhangkhoee et al., 2003; Feng et al., 2008). Thus, it is important to examine 
some molecular biomarkers of the putative cardiac alterations. In this study, we evaluated 
cardiac mRNA levels of TGF-β1, TSP-1, pro-collagen III, CTGF and brain BNP, which 
have been associated with cardiac hypertrophy and/or fibrosis. 
It has been shown that TGF-β1 plays a role in cell growth, differentiation, apoptosis, 
inflammatory processes, and gene expression (Lawrence, 1996; Bujak and Frangogiannis, 
2007). TGF-β1 activation has consistent implications in diabetic cardiomyopathy. It is 
becoming increasingly apparent that TGF-β1 represents a key mediator of cardiac 
adaptation to a dysmetabolic environment and/or hemodynamic overload. TGF-β1 has pro-
fibrotic properties and induces the expression of many matrix proteins, including 
collagens. The composition of extracellular matrix, a complex network of structural 
proteins, mainly collagen type I and III in the myocardium provides architectural support 
for the myocardium and plays an important role in myocardial function (Pauschinger et al., 
1999). In the hearts of patients with diabetes, collagen remodeling mainly as a result of an 
increase in collagen type III occurs in the perimysium and perivascular region (Shimizu et 
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al., 1993). Several studies have demonstrated an accumulation of collagens including 
collagen type III in diabetic cardiomyopathy, which has been related to left-ventricular 
diastolic and systolic dysfunction (Mizushige et al., 2000; Westermann et al., 2007).TSP-1 
is a matricellular glycoprotein that influences cellular phenotype and the structure of the 
extracellular matrix (Lawler, 2002). TSP-1 is a trimer of disulfide-linked 180 kD subunits, 
which consists of three identical polypeptide chains linked by disulfide bonds. Each chain 
is composed of six distinct structural and functional domains. It has been reported that high 
glucose stimulated TGF-β1 bioactivation by fibroblasts through upregulation of TSP-1. 
Recently, Tang et al. (2011) showed that high ambient glucose leads to upregulation of 
collagen III, which is mediated by TGF-β1. Indeed the TSP-1 is involved in this process 
through up-regulating the production of TGF-β1. CTGF is another potent profibrotic 
protein and play important roles in tissue and organ fibrosis. CTGF is increasingly being 
implicated in structural and functional abnormality of the heart in diabetes, and has diverse 
biological actions including the regulation of fibroblast proliferation, angiogenesis collagen 
synthesis, extracellular matrix deposition and cellular apoptosis. The expression of CTGF 
is increased in the myocardium of rats with STZ-induced diabetes (Leask et al., 2002; Way 
et al., 2002). Upregulation of CTGF can be mediated by hyperglycemia, ROS, Ang II, 
VEGF, PKC, AGEs and also by TGF-β1. Finally, BNP is among the most relevant 
molecular markers of cardiac hypertrophy. BNP is a peptide hormone released from the 
cardiac ventricles in response to pressure and volume overload, which may trigger cardiac 
hypertrophy in HSu-treated rats.  
In our study, we found no statistically significant difference in cardiac mRNA 
expression of TGF-β1, TSP-1, pro-collagen III and CTGF between the HSu and the 
Control rats, despite a trend to higher values in the HSu animals for all the markers, 
accompanied by a similar profile in serum TGF-β1 concentration. Moreover, BNP mRNA 
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levels were significantly higher in the HSu group versus the Control. As previously 
commented, the heart and LV weight of the HSu-treated rats showed higher values than 
those found for the Control animals, being statistically significant the changes of heart 
weight and LVW/BW. Even considering that LV weights could be influenced by the 
variability of the cut, whole heart weight/body weight are feasible measures, and showed a 
trend to higher values in the HSu-treated rats. Thus, collectively, this data indicate that 9 
weeks of sucrose diet might be a short period to promote pronounced changes on cardiac 
trophism, but the initial changes might be already in course, being BNP the earlier 
biomarker of those changes. A longer time of diet exposure might most probably confirm 
the effects of high-sucrose diet on cardiac hypertrophy and fibrosis, but after 9 weeks the 
earlier changes has already started to begin. Other studies have already shown that patients 
with T2DM have an increase in LVH, independent of other confounding factors, including 
hypertension (Devereux et al., 2000). However, LVH in the diabetic patient generally 
represents a more advanced stage of the disease and may manifest after a longer period.  
Other studies have previously tried to evaluate whether prediabetes, as measured by 
IFG, is associated with cardiac alterations. De Marco et a. (2011) found, evaluating a 
population-based sample of adolescents and young adults, that prediabetic individuals had 
a significantly higher prevalence of LVH than participants with normal fasting glucose, 
reflecting important target organ damage already present at an early phase of alteration of 
glucose metabolism. This fact is important, since there is a strong relation between LVH 
and adverse cardiovascular outcomes (Levy et al., 1990), recommending targeting 
prevention strategies in this subpopulation. Postprandial, but not fasting, hyperglycemia is 
known to be a better predictor of major cardiovascular events or total mortality, but the 
impact of postprandial or fasting glucose levels on LV diastolic function has not been 
elucidated (Coutinho et al., 1999; DECODE Study Group, 2001). Shimabukuro et al. 
Early cardiac effects of a high-sucrose diet in a rat model of prediabetes 
2012 
 
99 
(2011) showed, in humans, that impaired glucose tolerance, but not impaired fasting 
glucose, underlies left ventricular diastolic dysfunction, and Wu et al. (2007) previously 
described epidemiological evidence of altered cardiac autonomic function in subjects with 
IGT but not isolated IFG, as previously suggested (Fujita et al., 2007). Our data seem to be 
in agreement with this idea that IGT is associated with changes of the left ventricular. 
However, protein levels (measured by western blot or immunohistochemistry) of the 
markers analyzed, as well as other putatively relevant molecular markers could complete 
the information concerning the effects of HSu on cardiac hypertrophy and fibrosis in future 
works. 
Cardiac hypertrophy and fibrosis is usually associated with apoptosis. Physiological 
hypertrophy, such as exercise-induced cardiac hypertrophy, is a favorable adaptive change 
in the heart that accommodates it to increases in bodily demand and does not lead to heart 
failure. In contrast, pathological hypertrophy, such as pressure overload-induced 
hypertrophy, is a maladaptive response to pathological stimuli, and, if not ameliorated, 
usually leads to HF. Moreover, pathological cardiac hypertrophy may progress to HF 
because the cardiomyocytes are more susceptible to apoptosis (Kan et al., 2003). In our 
study, the pair in Bax and Bcl-2 was evaluated as a measure of impairment of apoptotic 
machinery. No significant changes in Bax and Bcl-2 cardiac mRNA expression were 
found. Whether these are or not related with the effect of insulin in the absence of 
hyperglycemia, deserve further evaluation. Therefore, it is known that insulin have anti-
apoptotic effects (Aikawa et al., 2000), which seem to be mediated by activation of 
different pathways, including the PI3K/Akt and MAPK/ERKs pathway, which are 
independently activated, and may exert their protective action in a cooperative fashion, by 
phosphorylating different serine residues of Bad, thus protecting cardiac myocyte from 
oxidative-stress-induced apoptosis. Although Bax and Bcl-2 are important molecules in the 
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apoptotic machinery, as among the most presented in the studies available on the literature, 
the lack of significant changes do not exclude the existence of perturbations in other 
important mediators of the process. 
Endothelial dysfunction is one of the mechanisms involved in the pathogenesis of 
DCM. Generically, endothelial dysfunction is characterized by impaired endothelium-
dependent vasodilation and usually reflects a reduced bioavailability of NO, which is an 
important vasodilator. Most of studies have been suggested that diabetes is associated with 
decreased expression of eNOS and consequently, a decreased production of NO, which is 
linked with impaired vasodilation; however, the source of NO in such setting is not clear. It 
is possible that NO from other sources, such as inducible NO synthase (iNOS), contribute 
to increased amounts of NO in diabetes. iNOS is an enzyme pathway with recognized 
implications in ROS production, particularly under inflammatory conditions and it is also 
involved in insulin resistance. Furthermore, Nagareddy et al. (2005) suggest that increased 
iNOS activity may contribute to an increased NO pool and depressed MAP and HR and 
endothelial dysfunction in 3 weeks STZ-induced diabetic rats. 
Activation of iNOS contributes to the pathogenesis of cardiovascular disease, 
probably because of excessive release of NO and generation of ROS. The expression of 
iNOS is upregulated by most, if not all, inducers of insulin resistance, including 
proinflammatory cytokines, obesity, FFAs, hyperglycemia, endotoxins and oxidative stress 
(Elizalde et al., 2000; Shimabukuro et al., 1998; Sharma et al., 1995; Xie et al., 1994, 
Haidara et al., 2010). Perreault and Marette (2001) demonstrated that elevated expression of 
iNOS was associated with development of muscle insulin resistance in high-fat diet-fed 
mice. Futhermore, iNOS mRNA is highly expressed in heart of obese Zucker diabetic fatty 
rats. In addition, iNOS deficiency protects from high-fat diet-induced insulin resistance in 
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the obese Zucker rat model (Zhou et al., 2000). These clearly demonstrate the important 
role of iNOs in insulin resistance.  
In our study, no significant change of cardiac iNOS mRNA levels was found 
between Hsu-treated rats and the Control ones, despite a trend to higher values in the 
insulin resistant animals. Lee et al. (2009) suggest that upregulation of iNOS may be a 
protective mechanism against excessive contraction, abnormal signaling resulting from 
oxidative stress and due to enhanced inflammation in the diabetic vasculature. Whether 
this hypothetic protection is present or nor in our model, deserves additional research. 
Therefore, future work should confirm the trend encountered, which might be 
complemented with supplementary measures. In fact, it would be interesting to measure 
eNOS mRNA expression and/or eNOS activity in these experimental conditions, in order 
to estimate NO availability in these conditions of insulin resistance, as well as the 
contribution of endothelial dysfunction to changes in early stages of DCM. 
Endothelial dysfunction is also assessed by measurement of elevated levels of 
cellular adhesion molecules (CAMs), including ICAM-1 and VCAM-1. Elevated levels of 
CAMs have been a consistent finding in cross-sectional studies of patients with type 2 
diabetes (Albertini et al., 1998; Caballero et al., 1999) and nondiabetic subjects at 
increased risk of diabetes, including subjects with impaired glucose tolerance, and in 
nondiabetic first-degree relatives of patients with type 2 diabetes (Caballero et al., 1999; 
Vehkavaara et al., 1999 Balletshofer et al., 2000). Elevated levels of CAMs predict the 
incident development of CVD events independent of standard CVD risk factors (Hwang et 
al., 1997). Our results showed no differences in ICAM-1 and VCAM-1 cardiac mRNA 
expression between the two groups, suggesting that this could be later markers of the 
changes, if implicated. 
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Angiogenesis is a key component of organ development, tissue repair and disease. 
Increased vascular permeability is one of the first steps in new vessel creation. VEGF, 
through vascular fenestration and tight junction modulation, mediates angiogenesis by 
increasing vascular permeability to water and large molecular weight proteins, assisting 
normal tissue repair and extracellular remodeling (Akhavani et al., 2007; Bates and Harper, 
2002). However, increased vascular permeability associated with pathological 
angiogenesis contributes to organ pathology and vascular disease (Bates and Harper, 2002; 
Simo´ et al., 2006). For more than a decade, the role of vascular endothelial growth factor 
(VEGF) in the regulation of angiogenesis has been the object of intense investigation 
(Ferrara, 2004). Recent evidence indicates that new vessel growth and maturation are 
highly complex and coordinated processes, requiring the sequential activation of a series of 
receptors by numerous ligands in endothelial and mural cells (Carmeliet, 2003; Jain, 2003). 
However, VEGF signaling often represents a critical rate-limiting step in physiological 
angiogenesis and is one the most important growth factors, which affects all aspects of 
angiogenesis including matrix degradation and endothelial cell migration and proliferation 
(Neufeld et al., 1999). Our results showed a significant increment in serum VEGF levels in 
HSu compared with Control. These data may be explained by the fact that in insulin 
resistant-state, insulin is no longer capable of antagonizing VEGF level (Wan et al., 2004). 
Although non-significant, a trend to higher levels of cardiac tissue VEGF mRNA levels in 
the HSu-related rats was found, which deserve future confirmation, eventually in rats 
treated for longer periods with high-sucrose diet, as the changes suggested by our data are 
in opposition to those found in other studies. Therefore, VEGF overexpression was found 
in cardiac myocytes and arteriolar smooth muscle cells following MI in non-diabetic 
patients (Shinohara et al., 1996). However, the expression of VEGF protein and mRNA, as 
well as its receptors, are significantly decreased in the myocardium of both diabetic and 
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insulin-resistant non-diabetic rats (Chou et al., 2002), suggesting that, in diabetic patients, 
the normal molecular processes which regulate angiogenesis may be impaired 
(downregulated). 
Accumulating evidences suggest that chronic low-grade inflammation is involved not 
only in obesity and T2DM pathophysiology, but also in DCM development. Elevated 
inflammatory cytokines have been found in circulation and in the diabetic hearts o T2DM 
patients (Yu et al., 2011; Mano et al., 2011). Furthermore, inflammatory mediators, such as 
IL1-β and TNF-α, have been implicated in diabetic cardiomyopathy, increasing epicardial 
thickness and promoting myocyte contractile dysfunction, thus depressing myocardial 
function, contributing to HF (Westermann et al., 2006). Additionally, cardiac 
overexpression of TNF-α has been associated with cardiac hypertrophy and fibrosis, as 
well with left ventricular dysfunction (Yokoyama et al., 1997; Sun et al., 2004) and IL-6 
has been also described as an inducer of myocardial damage by promoting LV dysfunction 
and cardiac hypertrophy under acute myocardial infarction (Younce et al., 2010). In our 
study, however, no significant changes were found concerning serum levels of IL-6 and 
IFN- and cardiac mRNA expression of IL-6 and TNF-α, which was accompanied by a 
reduction of serum CRP contents in the HSu-treated rats. Thus, according to our data, 
which might be further completed with additional markers (such as other interleukins and 
the NF-kB, which is an important mediator of the inflammatory process), inflammation is 
not the key factor of early changes related to cardiomyopathy. 
One of the major mechanisms associated with DCM is the generation of ROS and 
oxidative stress. Increased ROS and reduced antioxidant defenses have been shown in 
T2DM patients, which might be due to hyperglycemia, glucose autoxidation, and elevated 
levels of FFAs (Davı et al. 2005; Jay et al. 2006). Over-generation of mitochondrial ROS 
has been also shown in several tissues exposed to hyperglycemia (Camici et al. 2007). 
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Hyperglycemia-induced overproduction of ROS, such as superoxide, by the mitochondrial 
electron transport chain could be one of the first and key episodes in the activation of all 
other pathways involved in the pathogenesis of diabetic complications (Piconi et al. 2003; 
Rolo and Palmeira 2006). Increased mitochondrial protein nitration, hydrogen peroxide 
production, and reduced glutathione levels have been observed to occur in diabetic hearts 
(Nishio et al. 2004). In hyperglycemia associated with diabetes mellitus, there is activation 
of the polyol pathway, hexosamine pathway, protein kinase C, and increased AGEs 
(Khullar et al., 2010). Increased ROS production was also shown to be associated with 
increased apoptosis in hearts of ob/ob and db/db mice (Barouch et al. 2003). It has been 
proposed that ROS-mediated cell death could promote abnormal cardiac remodeling, 
which ultimately may contribute to the characteristic morphological and functional 
abnormalities that are associated with diabetic cardiomyopathy (Boudina and Abel, 2007). 
Under diabetic conditions, there is an inflammatory response by oxidative mechanisms, 
which may contribute to the development of diabetic cardiomyopathy (Khansari et al. 
2009). Hyperglycemia has been observed to be associated with greater systemic 
inflammation that may be an important contributor to cardiovascular risk among diabetic 
patients. Although the mechanisms behind this association are not clearly understood, 
hyperglycemia has been shown to increase the binding of inflammatory cells (such as the T 
cells and mononuclear phagocytes) to the endothelium and to increase the inflammatory 
cytokine production by monocytes (Basta et al. 2004; Rolo and Palmeira, 2006). However, 
in a state of hyperglycemia and insulin resistance, without hyperglycemia, as occurs in 
early stages of diabetes (prediabetes), the contribution of ROS and consequent oxidative 
stress to the cardiac changes remain to be elucidated. 
We have measure serum and cardiac tissues markers of redox status (lipid 
peroxidation and antioxidants), in order to evaluate the contribution of a putative 
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impairment of ROS/antioxidants equilibrium in this state of insulin resistance without 
hyperglycemia. We found a trend to increased MDA (a marker of lipid peroxidation) levels 
in both the serum and the heart tissue of Hsu-treated rats vs the control. However, a 
significantly increased amount of serum TAS (a measure of total antioxidant capacity) was 
also encountered in the HSu rats, which seem to reflect a compensatory response against 
the eventual increment of ROS. The serum results were accompanied by increased cardiac 
SOD mRNA expression, together with decreased HNE (also a lipid peroxidation marker) 
and RAGE mRNA expression. 
The results of our study are not consistent with previous studies. It has been shown 
that rats fed a high sucrose diet had reduced heart antioxidant enzyme activity (Cu-Zn-
SOD), greater hear susceptibility to peroxidation and/or decreased protection from non-
enzymatic or enzymatic antioxidants (Bussereoles et al., 2002). In the heart tissues of 
diabetic rats, upregulation of RAGE has been found and it is strongly associated with 
impaired cardiac function (Simm et al., 2004). Activation of RAGE is known to influence 
myocardial calcium homeostasis and contribute to interstitial fibrinogenesis in the diabetic 
heart ((Petrova et al., 2002, Candido et al., 2003). Indeed, increased gene expression of 
RAGE was observed in high-fat feed animals and inhibition of prevention of RAGE 
activation in knockout animals able to prevent the induction of inflammation, oxidative 
stress and mitochondrial dysfunction the heart associated with high fat feeding (Tikellis et 
al., 2008).  
We must note that our model present hyperinsulinemia, which is still able to 
normalize blood glucose levels, at least viewed by the fast glycemia, despite impaired 
glucose tolerance. Thus, in a model like this, it seems that the putative (since the data is 
only a trend to increased MDA) generation of reactive species is yet compensated by 
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additional generation of antioxidants, viewed by increased serum TAS and cardiac mRNA 
expression of SOD. Furthermore, RAGE mRNA downexpression in the cardiac tissue 
might eventually be also viewed as a compensatory mechanism, in order to protect the 
cardiac tissue.  
Oxidative stress has been indicated as one of the main pathophysiological implicated 
in the development of insulin resistance and further cardiovascular toxicity. In this model 
of prediabetic insulin-resistance induced by sucrose consumption, if the trend to increased 
values of MDA in serum and heart are representative of an initial increased generation of 
ROS, then it is an earlier phase of the damaging process, in which there is yet a 
compensatory antioxidant defense. However, we cannot exclude the possibility that longer 
exposure times of sucrose may lead to reduction of these antioxidant defence mechanisms 
and, consequently, to toxic effects induced by oxidative stress aggravating cardiac 
function.  
Hyperglycemia has been indicated as one of the major causes of DCM, due to 
activation of several mechanisms, leading to an increase in oxidative stress by several 
pathways, such as increased activation of the polyol and hexosamine pathways, increased 
formation of AGEs and activation of classical isoforms of PKC, which induce increased 
production of mitochondrial ROS, nonenzymatic glycation of proteins and glucose auto-
oxidation. Activation of these pathways corresponds to an increased glucotoxicity, which 
may cause cellular injury. If sustained hyperglycemia, is a pivotal factor for the cardiac 
changes that evolutes further to DCM, then the lack of substantial cardiac impairment in 
this model could be explained by the limited glucose dysfunction (impaired glucose 
tolerance) of this prediabetes/insulin resistance state. However, it will be crucial to better 
evaluate this putative earlier oxidative stress, using additional markers, in order to further 
Early cardiac effects of a high-sucrose diet in a rat model of prediabetes 
2012 
 
107 
assess if it is present and if has an effective impact on the cardiac tissue, since some other 
markers, mainly of hypertrophy and fibrosis, seem to be already affected. 
Figure 34 summarizes the main results obtained concerning the animal model 
characterization as well as the impact of high-sucrose diet on the cardiac tissue.  
 
 
Figure 34. Summary scheme of the obtained results in this study. 
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1. The animal model chosen to mimic a situation of prediabetes/ insulin resistance, 
consisting of 35% sucrose consumption during 9 weeks, presented as main metabolic 
features: a) Fasting normoglycemia; b) Impaired glucose tolerance; c) Hyperinsulinemia; 
d) Hypertryglyceridemia and e) Absence of obesity and hypertension. 
2. This animal model presented some alterations suggestive of hypertrophy/fibrosis, 
namely in the left ventricle. Therefore, apart from the trend to increased values of several 
markers of hypertrophy/fibrosis, there was a significant increment in the BNP mRNA 
expression in the HSu group, which was accompanied by increased heart and left ventricle 
mass. 
3. Despite some variations in the values encountered for markers endothelial lesion, 
angiogenesis and inflammation in the HSu-treated rats, the differences were not 
statistically significant and, thus, these pathways seem to be less relevant at this stage of 
dysmetabolism concerning an impact on the cardiac tissue. 
4. Some of the data encountered is suggestive that the oxidative stress, and 
compensated antioxidant response, are the more pronounced change at this stage. 
Therefore, increased serum total antioxidant capacity and cardiac mRNA expression of 
SOD, together with decreased HNE (a lipid peroxidation marker) and RAGE (receptor of 
AGEs) mRNA expression are eventual indicator of a compensatory antioxidant response. 
This response might have been produced as a result for an increased ROS, as the variations 
of serum and heart MDA suggest, although not yert totaly confirmed. 
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As summary conclusion, this animal model of prediabetes/insulin resistance, induced 
by high sucrose consumption during 9 weeks, could be an important tool to evaluate the 
impact of dysmetabolism (mainly hyperinsulinemia and impaired glucose tolerance) on 
cardiac function/performance, without confounding factors such as obesity and 
hypertension. However, if hyperglycemia is the major driving force for the cardiac changes 
underlying cardiomyopathy, most probably due to induction of oxidative stress, has is 
suggested, then the lack of substantial cardiac impairment in this model could be explained 
by the limited glucose impairment of this prediabetes/insulin resistance state. However 
additional studies are needed to better understand the underlying molecular and cellular 
mechanisms responsible for the effects of HSu on this earlier phase of DCM, namely 
evaluation other durations of diet exposure, as well as other relevant markers of cardiac 
impairment. 
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